Jump to content
RemedySpot.com

Re: Has the ultimate cancer cure arrived?

Rate this topic

Guest guest

By Guest guest
in Health, Medicine and Natural Healing 01

 Share

Recommended Posts

Guest guest

Guest guest

Posted
Posted

Green,

I thought ozone was a big cancer breakthrough -- 120 years ago! And,

that nothing better has come along! ;-)

jim :)

green1 wrote:

>

> Hello Folks,

>

> Listmember

> pkelly@...

> just posted this forward on the medical qi gong list.

> It looks like a big breakthrough in cancer therapy.

>

> Green

>

> This is an interesting post from the Cancercure support group.

> Have a great weekend.

>

-----

The TRUTH in 11 words:

Inside every older person is a younger person wondering what happened!

-- anon

jlambert@... http://www.entrance.to/madscience

http://www.entrance.to/poetry

Link to comment
Share on other sites
Guest guest

Guest guest

Posted
Posted

Jim, I agree with you that ozone is effective cancer therapy,

and that's one of the reasons I set myself up with an ozone

sauna. One thing I especially like about it is that once the

initial investment is made, this wide-spectrum therapy is

virtually cost-free and totally accessible, at my convenience,

and within my own control without leaving my home.

As for whether ozone is the overall most effective treatment

for cancer, I honestly don't know, but I suspect it may be. I

do know that alternatives are generally more successful in

treating cancer than are mainstream medicine's surgery,

radiation and chemotherapy, often markedly so. I find

cancer therapy of general interest and am always ready

to make note of new developments and to share the

information I've collected. When people find themselves

faced with cancer, they want to know what their options are.

In any case, if the claims made for methylglyoxal are true,

and it sounds to me that they are, a substance which kills

cancer cells while not harming normal cells will go a long

way to treat cancer, if accepted into the mainstream.

That's not to say it will reverse the conditions which resulted

in cancer in the first place, but it could still help a lot of

people, and seems worth making note of. If you or anyone

wants to buttress the case for ozone being the most effective

therapy available for cancer, or provide more information about

those few instances when it may be contraindicated, I'm quite

interested and more than willing to listen.

Green

~^~^~^~^

Green,

I thought ozone was a big cancer breakthrough -- 120 years ago! And,

that nothing better has come along! ;-)

jim :)

green1 wrote:

>

> Hello Folks,

>

> Listmember

> pkelly@...

> just posted this forward on the medical qi gong list.

> It looks like a big breakthrough in cancer therapy.

>

> Green

>

> This is an interesting post from the Cancercure support group.

> Have a great weekend.

>

Link to comment
Share on other sites
Guest guest

Guest guest

Posted
Posted

Dear Jim,

It is nice to see the Indian researchers finding something that

can destroy cancer cells, because we can use all the help we can

get.

But, since the CAUSE of the cancer (cellular hypoxia due to built-up

toxins)is not being addressed, it will recur in these people.

The beauty of ozone therapy is that it deals with the cancer cells AND with

the cause, by oxidizing toxins and oxygenating the surrounding cells.

Best of Health!

Dr. Saul Pressman, DCh, LOH

Re: Has the ultimate cancer cure arrived?

> Green,

>

> I thought ozone was a big cancer breakthrough -- 120 years ago! And,

> that nothing better has come along! ;-)

>

> jim :)

>

> green1 wrote:

> >

> > Hello Folks,

> >

> > Listmember

> > pkelly@...

> > just posted this forward on the medical qi gong list.

> > It looks like a big breakthrough in cancer therapy.

> >

> > Green

> >

> > This is an interesting post from the Cancercure support group.

> > Have a great weekend.

> >

> -----

> The TRUTH in 11 words:

> Inside every older person is a younger person wondering what happened!

> -- anon

>

> jlambert@... http://www.entrance.to/madscience

> http://www.entrance.to/poetry

>

>

Link to comment
Share on other sites
Guest guest

Guest guest

Posted
Posted

Curiously, the source for this chemical (Methylglyoxal synthase) is E.

Coli... named by Rife as a pleomorphic from the Bx cancer virus...

HEADER LYASE 19-FEB-99 1B93

TITLE METHYLGLYOXAL SYNTHASE FROM ESCHERICHIA COLI

COMPND MOL_ID: 1;

COMPND 2 MOLECULE: METHYLGLYOXAL SYNTHASE;

COMPND 3 CHAIN: A, B, C;

COMPND 4 EC: 4.2.99.11;

COMPND 5 ENGINEERED: YES

SOURCE MOL_ID: 1;

SOURCE 2 ORGANISM_SCIENTIFIC: ESCHERICHIA COLI;

SOURCE 3 STRAIN: LE392;

SOURCE 4 CELLULAR_LOCATION: CYTOPLASM;

SOURCE 5 GENE: MGSA;

SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI;

SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3);

SOURCE 8 EXPRESSION_SYSTEM_CELLULAR_LOCATION: CYTOPLASM;

SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID;

SOURCE 10 EXPRESSION_SYSTEM_VECTOR: PET16B;

SOURCE 11 EXPRESSION_SYSTEM_PLASMID: PETMGSWT;

SOURCE 12 EXPRESSION_SYSTEM_GENE: MGSA

KEYWDS GLYCOLYTIC BYPASS, METHYLGLYOXAL, LYASE

EXPDTA X-RAY DIFFRACTION

AUTHOR D.SAADAT,D.H.T.HARRISON

REVDAT 4 25-FEB-00 1B93 1 ATOM

REVDAT 3 18-FEB-00 1B93 1 HEADER COMPND REMARK

REVDAT 2 24-MAR-99 1B93 1 JRNL

REVDAT 1 16-MAR-99 1B93 0

JRNL AUTH D.SAADAT,D.H.T.HARRISON

JRNL TITL THE CRYSTAL STRUCTURE OF METHYGLYOXAL SYNTHASE

JRNL TITL 2 FROM ESCHERICHIA COLI

JRNL REF STRUCTURE (LONDON) V. 7 309 1999

JRNL REFN ASTM STRUE6 UK ISSN 0969-2126

REMARK 1

REMARK 2

REMARK 2 RESOLUTION. 1.90 ANGSTROMS.

REMARK 3

REMARK 3 REFINEMENT.

REMARK 3 PROGRAM : X-PLOR 3.851

REMARK 3 AUTHORS : BRUNGER

REMARK 3

REMARK 3 DATA USED IN REFINEMENT.

REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.90

REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.00

REMARK 3 DATA CUTOFF (SIGMA(F)) : 2.000

REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 10000000.000

REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0010

REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 82.1

REMARK 3 NUMBER OF REFLECTIONS : 53546

REMARK 3

REMARK 3

REMARK 3 FIT TO DATA USED IN REFINEMENT.

REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT

REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM

REMARK 3 R VALUE (WORKING SET) : 0.181

REMARK 3 FREE R VALUE : 0.202

REMARK 3 FREE R VALUE TEST SET SIZE (%) : 7.100

REMARK 3 FREE R VALUE TEST SET COUNT : 3788

REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.003

REMARK 3

REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN.

REMARK 3 TOTAL NUMBER OF BINS USED : 6

REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.80

REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.91

REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 42.10

REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 4163

REMARK 3 BIN R VALUE (WORKING SET) : 0.2810

REMARK 3 BIN FREE R VALUE : 0.2920

REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 7.40

REMARK 3 BIN FREE R VALUE TEST SET COUNT : 335

REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.016

REMARK 3

REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT.

REMARK 3 PROTEIN ATOMS : 3399

REMARK 3 NUCLEIC ACID ATOMS : 0

REMARK 3 HETEROGEN ATOMS : 5

REMARK 3 SOLVENT ATOMS : 238

REMARK 3

REMARK 3 B VALUES.

REMARK 3 FROM WILSON PLOT (A**2) : 12.60

REMARK 3 MEAN B VALUE (OVERALL, A**2) : 24.00

REMARK 3 OVERALL ANISOTROPIC B VALUE.

REMARK 3 B11 (A**2) : 0.00000

REMARK 3 B22 (A**2) : 0.00000

REMARK 3 B33 (A**2) : 0.00000

REMARK 3 B12 (A**2) : 0.00000

REMARK 3 B13 (A**2) : 0.00000

REMARK 3 B23 (A**2) : 0.00000

REMARK 3

REMARK 3 ESTIMATED COORDINATE ERROR.

REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.19

REMARK 3 ESD FROM SIGMAA (A) : 0.230

REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00

REMARK 3

REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR.

REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.20

REMARK 3 ESD FROM C-V SIGMAA (A) : 0.22

REMARK 3

REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES.

REMARK 3 BOND LENGTHS (A) : 0.006

REMARK 3 BOND ANGLES (DEGREES) : 1.20

REMARK 3 DIHEDRAL ANGLES (DEGREES) : 24.90

REMARK 3 IMPROPER ANGLES (DEGREES) : 0.65

REMARK 3

REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED

REMARK 3

REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA

REMARK 3 MAIN-CHAIN BOND (A**2) : 1.45 ; 1.500

REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.28 ; 2.000

REMARK 3 SIDE-CHAIN BOND (A**2) : 2.98 ; 2.000

REMARK 3 SIDE-CHAIN ANGLE (A**2) : 4.52 ; 2.500

REMARK 3

REMARK 3

REMARK 3 NCS MODEL : RESTRAINTS

REMARK 3

REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT

REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL

REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL

REMARK 3

REMARK 3 PARAMETER FILE 1 : PARHCSDX.PRO

REMARK 3 PARAMETER FILE 2 : TOPPAR2:FMT.PAR

REMARK 3 PARAMETER FILE 3 : TOPPAR2:IPS.PAR

REMARK 3 PARAMETER FILE 4 : NULL

REMARK 3 TOPOLOGY FILE 1 : TOPHCSDX.PRO

REMARK 3 TOPOLOGY FILE 2 : TOPH19.SOL

REMARK 3 TOPOLOGY FILE 3 : TOPPAR2:FMT.TOP

REMARK 3 TOPOLOGY FILE 4 : TOPPAR2:IPS.TOP

REMARK 3

REMARK 3 OTHER REFINEMENT REMARKS: BULK SOLVENT MODEL USED

REMARK 4

REMARK 4 1B93 COMPLIES WITH FORMAT V. 2.3, 09-JULY-1998

REMARK 7

REMARK 100

REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 23-FEB-1999.

REMARK 100 THE RCSB ID CODE IS RCSB000505.

REMARK 200

REMARK 200 EXPERIMENTAL DETAILS

REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION

REMARK 200 DATE OF DATA COLLECTION : NULL

REMARK 200 TEMPERATURE (KELVIN) : 277.0

REMARK 200 PH : 6.50

REMARK 200 NUMBER OF CRYSTALS USED : 4

REMARK 200

REMARK 200 SYNCHROTRON (Y/N) : N

REMARK 200 RADIATION SOURCE : NULL

REMARK 200 BEAMLINE : NULL

REMARK 200 X-RAY GENERATOR MODEL : RIGAKU RU200

REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M

REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418

REMARK 200 MONOCHROMATOR : GRAPHITE MONOCHROMATOR

REMARK 200 OPTICS : NULL

REMARK 200

REMARK 200 DETECTOR TYPE : LATENT IMAGE PHOSPH

REMARK 200 DETECTOR MANUFACTURER : RIGAKU

REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO

REMARK 200 DATA SCALING SOFTWARE : SCALEPACK

REMARK 200

REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 58374

REMARK 200 RESOLUTION RANGE HIGH (A) : 1.800

REMARK 200 RESOLUTION RANGE LOW (A) : 30.000

REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000

REMARK 200

REMARK 200 OVERALL.

REMARK 200 COMPLETENESS FOR RANGE (%) : 89.5

REMARK 200 DATA REDUNDANCY : 4.000

REMARK 200 R MERGE (I) : 0.07700

REMARK 200 R SYM (I) : 0.07700

REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST

RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.80

REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.88 REMARK 200

COMPLETENESS FOR SHELL (%) : 36.8 REMARK 200 DATA REDUNDANCY IN SHELL : NULL

REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) :

NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL:

SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MIRAS

REMARK 200 SOFTWARE USED: XTALVIEW REMARK 200 STARTING MODEL: NULL REMARK

200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT

CONTENT, VS (%): NULL REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA):

3.40 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290

REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE

GROUP: P 65 2 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM

OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,2/3+Z REMARK 290

3555 -X+Y,-X,1/3+Z REMARK 290 4555 -X,-Y,1/2+Z REMARK 290 5555 Y,-X+Y,1/6+Z

REMARK 290 6555 X-Y,X,5/6+Z REMARK 290 7555 Y,X,2/3-Z REMARK 290 8555

X-Y,-Y,-Z REMARK 290 9555 -X,-X+Y,1/3-Z REMARK 290 10555 -Y,-X,1/6-Z REMARK

290 11555 -X+Y,Y,1/2-Z REMARK 290 12555 X,X-Y,5/6-Z REMARK 290 REMARK 290

WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290

REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE

FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN

THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES.

REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1

0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000

1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000

REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2

0.000000 0.000000 1.000000 103.98667 REMARK 290 SMTRY1 3 -0.500000 0.866025

0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000

REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 51.99333 REMARK 290 SMTRY1

4 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000

0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 77.99000

REMARK 290 SMTRY1 5 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2

5 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000

1.000000 25.99667 REMARK 290 SMTRY1 6 0.500000 -0.866025 0.000000 0.00000

REMARK 290 SMTRY2 6 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6

0.000000 0.000000 1.000000 129.98333 REMARK 290 SMTRY1 7 -0.500000 0.866025

0.000000 0.00000 REMARK 290 SMTRY2 7 0.866025 0.500000 0.000000 0.00000

REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 103.98667 REMARK 290 SMTRY1

8 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 8 0.000000 -1.000000

0.000000 0.00000 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 0.00000

REMARK 290 SMTRY1 9 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2

9 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 9 0.000000

0.000000 -1.000000 51.99333 REMARK 290 SMTRY1 10 0.500000 -0.866025 0.000000

0.00000 REMARK 290 SMTRY2 10 -0.866025 -0.500000 0.000000 0.00000 REMARK 290

SMTRY3 10 0.000000 0.000000 -1.000000 25.99667 REMARK 290 SMTRY1

11 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 11 0.000000

1.000000 0.000000 0.00000 REMARK 290 SMTRY3 11 0.000000 0.000000 -1.000000

77.99000 REMARK 290 SMTRY1 12 0.500000 0.866025 0.000000 0.00000 REMARK 290

SMTRY2 12 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 12 0.000000

0.000000 -1.000000 129.98333 REMARK 290 REMARK 290 REMARK: NULL REMARK 295

REMARK 295 NON-CRYSTALLOGRAPHIC SYMMETRY REMARK 295 THE TRANSFORMATIONS

PRESENTED ON THE MTRIX RECORDS BELOW REMARK 295 DESCRIBE

NON-CRYSTALLOGRAPHIC RELATIONSHIPS AMONG ATOMS REMARK 295 IN THIS ENTRY.

APPLYING THE APPROPRIATE MTRIX REMARK 295 TRANSFORMATION TO THE RESIDUES

LISTED FIRST WILL YIELD REMARK 295 APPROXIMATE COORDINATES FOR THE RESIDUES

LISTED SECOND. REMARK 295 CHAIN IDENTIFIERS GIVEN AS " ? " REFER TO CHAINS FOR

WHICH REMARK 295 ATOMS ARE NOT FOUND IN THIS ENTRY. REMARK 295 REMARK 295

APPLIED TO TRANSFORMED TO REMARK 295 TRANSFORM CHAIN RESIDUES CHAIN RESIDUES

RMSD REMARK 295 SSS REMARK 295 M 1 A 1 .. 144 B 1 .. 144 REMARK 295 REMARK

295 WHERE SSS -> COLUMNS 8-10 OF MTRIX RECORDS REMARK 300 REMARK 300

BIOMOLECULE: 1 REMARK 300 THIS ENTRY CONTAINS THE CRYSTALLOGRAPHIC

ASYMMETRIC UNIT REMARK 300 WHICH CONSISTS OF 3 CHAIN(S). SEE REMARK 350 FOR

REMARK 300 INFORMATION ON GENERATING THE BIOLOGICAL MOLECULE(S). REMARK 350

REMARK 350 GENERATING THE BIOMOLECULE REMARK 350 COORDINATES FOR A COMPLETE

MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT

OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY

APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH

NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN.

REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 APPLY THE FOLLOWING TO

CHAINS: A, B, C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000

REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1

0.000000 0.000000 1.000000 0.00000 REMARK 350 BIOMT1 2 0.500000 -0.866025

0.000000 61.67000 REMARK 350 BIOMT2 2 -0.866025 -0.500000 0.000000 106.81557

REMARK 350 BIOMT3 2 0.000000 0.000000 -1.000000 181.97667 REMARK 465 REMARK

465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN

THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK

465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK

465 M RES C SSSEQI REMARK 465 ASP A 149 REMARK 465 ARG A 150 REMARK 465 LEU

A 151 REMARK 465 LYS A 152 REMARK 465 LYS B 152 REMARK 465 ARG C 145 REMARK

465 TYR C 146 REMARK 465 LEU C 147 REMARK 465 ALA C 148 REMARK 465 ASP C 149

REMARK 465 ARG C 150 REMARK 465 LEU C 151 REMARK 465 LYS C 152 REMARK 470

REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING

ATOMS(M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER;

SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI

ATOMS REMARK 470 LEU A 36 CG CD1 CD2 REMARK 470 GLN A 144 CG CD OE1 NE2

REMARK 470 GLN B 24 CG CD OE1 NE2 REMARK 470 GLU B 38 CG CD OE1 OE2 REMARK

470 ARG B 54 CG CD NE CZ NH1 NH2 REMARK 470 GLN B 144 CG CD OE1 NE2 REMARK

470 ARG B 145 CG CD NE CZ NH1 NH2 REMARK 470 MET C 1 CG SD CE REMARK 470 LEU

C 36 CG CD1 CD2 REMARK 470 GLN C 39 CG CD OE1 NE2 REMARK 470 ASN C 50 CG OD1

ND2 REMARK 470 ARG C 54 CG CD NE CZ NH1 NH2 REMARK 470 GLN C 144 CG CD OE1

NE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC:

COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF

THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED

VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME;

C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE).

REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:

(10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500

EXPECTED VALUES: ENGH AND HUBER, 1991 REMARK 500 REMARK 500 M RES CSSEQI

ATM1 ATM2 ATM3 REMARK 500 LEU A 8 N - CA - C ANGL. DEV. =-11.6 DEGREES

REMARK 500 HIS A 13 N - CA - C ANGL. DEV. = -8.8 DEGREES REMARK 500 TYR A 43

N - CA - C ANGL. DEV. = -8.0 DEGREES REMARK 500 ILE A 87 N - CA - C ANGL.

DEV. = -9.7 DEGREES REMARK 500 ASN A 113 N - CA - C ANGL. DEV. = 7.4 DEGREES

REMARK 500 ALA A 135 N - CA - C ANGL. DEV. = -8.8 DEGREES REMARK 500 THR B 4

N - CA - C ANGL. DEV. = -7.6 DEGREES REMARK 500 ARG B 6 N - CA - C ANGL.

DEV. = -7.5 DEGREES REMARK 500 HIS B 13 N - CA - C ANGL. DEV. = -9.2 DEGREES

REMARK 500 GLY B 46 N - CA - C ANGL. DEV. = 7.8 DEGREES REMARK 500 ILE B 87

N - CA - C ANGL. DEV. = -9.3 DEGREES REMARK 500 ASN B 113 N - CA - C ANGL.

DEV. = 7.8 DEGREES REMARK 500 ALA B 135 N - CA - C ANGL. DEV. = -9.7 DEGREES

REMARK 500 LEU C 8 N - CA - C ANGL. DEV. = -8.3 DEGREES REMARK 500 HIS C 13

N - CA - C ANGL. DEV. = -8.5 DEGREES REMARK 500 ILE C 87 N - CA - C ANGL.

DEV. = -9.1 DEGREES REMARK 500 ASN C 113 N - CA - C ANGL. DEV. = 7.5 DEGREES

REMARK 500 ALA C 135 N - CA - C ANGL. DEV. = -9.7 DEGREES REMARK 999 DBREF

1B93 A 1 152 SWS P37066 MGSA_ECOLI 1 152 DBREF 1B93 B 1 152 SWS P37066

MGSA_ECOLI 1 152 DBREF 1B93 C 1 152 SWS P37066 MGSA_ECOLI 1 152 SEQRES 1 A

152 MET GLU LEU THR THR ARG THR LEU PRO ALA ARG LYS HIS SEQRES 2 A 152 ILE

ALA LEU VAL ALA HIS ASP HIS CYS LYS GLN MET LEU SEQRES 3 A 152 MET SER TRP

VAL GLU ARG HIS GLN PRO LEU LEU GLU GLN SEQRES 4 A 152 HIS VAL LEU TYR ALA

THR GLY THR THR GLY ASN LEU ILE SEQRES 5 A 152 SER ARG ALA THR GLY MET ASN

VAL ASN ALA MET LEU SER SEQRES 6 A 152 GLY PRO MET GLY GLY ASP GLN GLN VAL

GLY ALA LEU ILE SEQRES 7 A 152 SER GLU GLY LYS ILE ASP VAL LEU ILE PHE PHE

TRP ASP SEQRES 8 A 152 PRO LEU ASN ALA VAL PRO HIS ASP PRO ASP VAL LYS ALA

SEQRES 9 A 152 LEU LEU ARG LEU ALA THR VAL TRP ASN ILE PRO VAL ALA SEQRES 10

A 152 THR ASN VAL ALA THR ALA ASP PHE ILE ILE GLN SER PRO SEQRES 11 A 152

HIS PHE ASN ASP ALA VAL ASP ILE LEU ILE PRO ASP TYR SEQRES 12 A 152 GLN ARG

TYR LEU ALA ASP ARG LEU LYS SEQRES 1 B 152 MET GLU LEU THR THR ARG THR LEU

PRO ALA ARG LYS HIS SEQRES 2 B 152 ILE ALA LEU VAL ALA HIS ASP HIS CYS LYS

GLN MET LEU SEQRES 3 B 152 MET SER TRP VAL GLU ARG HIS GLN PRO LEU LEU GLU

GLN SEQRES 4 B 152 HIS VAL LEU TYR ALA THR GLY THR THR GLY ASN LEU ILE

SEQRES 5 B 152 SER ARG ALA THR GLY MET ASN VAL ASN ALA MET LEU SER SEQRES 6

B 152 GLY PRO MET GLY GLY ASP GLN GLN VAL GLY ALA LEU ILE SEQRES 7 B 152 SER

GLU GLY LYS ILE ASP VAL LEU ILE PHE PHE TRP ASP SEQRES 8 B 152 PRO LEU ASN

ALA VAL PRO HIS ASP PRO ASP VAL LYS ALA SEQRES 9 B 152 LEU LEU ARG LEU ALA

THR VAL TRP ASN ILE PRO VAL ALA SEQRES 10 B 152 THR ASN VAL ALA THR ALA ASP

PHE ILE ILE GLN SER PRO SEQRES 11 B 152 HIS PHE ASN ASP ALA VAL ASP ILE LEU

ILE PRO ASP TYR SEQRES 12 B 152 GLN ARG TYR LEU ALA ASP ARG LEU LYS SEQRES 1

C 152 MET GLU LEU THR THR ARG THR LEU PRO ALA ARG LYS HIS SEQRES 2 C 152 ILE

ALA LEU VAL ALA HIS ASP HIS CYS LYS GLN MET LEU SEQRES 3 C 152 MET SER TRP

VAL GLU ARG HIS GLN PRO LEU LEU GLU GLN SEQRES 4 C 152 HIS VAL LEU TYR ALA

THR GLY THR THR GLY ASN LEU ILE SEQRES 5 C 152 SER ARG ALA THR GLY MET ASN

VAL ASN ALA MET LEU SER SEQRES 6 C 152 GLY PRO MET GLY GLY ASP GLN GLN VAL

GLY ALA LEU ILE SEQRES 7 C 152 SER GLU GLY LYS ILE ASP VAL LEU ILE PHE PHE

TRP ASP SEQRES 8 C 152 PRO LEU ASN ALA VAL PRO HIS ASP PRO ASP VAL LYS ALA

SEQRES 9 C 152 LEU LEU ARG LEU ALA THR VAL TRP ASN ILE PRO VAL ALA SEQRES 10

C 152 THR ASN VAL ALA THR ALA ASP PHE ILE ILE GLN SER PRO SEQRES 11 C 152

HIS PHE ASN ASP ALA VAL ASP ILE LEU ILE PRO ASP TYR SEQRES 12 C 152 GLN ARG

TYR LEU ALA ASP ARG LEU LYS HET IPS 301 5 HET FMT 201 3 HET FMT 202 3 HET

FMT 203 3 HET FMT 204 3 HET FMT 205 3 HET FMT 206 3 HET FMT 207 3 HETNAM IPS

INORGANIC PHOSPHATE GROUP HETNAM FMT FORMIC ACID FORMUL 4 IPS H1 O4 P1 2-

FORMUL 5 FMT 7(C1 H2 O2) FORMUL 12 HOH *217(H2 O1) HELIX 1 1 ASP A 20 ARG A

32 5 13 HELIX 2 2 GLN A 34 GLN A 39 1 6 HELIX 3 3 GLY A 46 THR A 56 5 11

HELIX 4 4 GLY A 66 MET A 68 5 3 HELIX 5 5 GLY A 70 SER A 79 1 10 HELIX 6 6

ASP A 99 VAL A 111 1 13 HELIX 7 7 VAL A 120 ILE A 127 1 8 HELIX 8 8 PRO A

130 ASN A 133 5 4 HELIX 9 9 TYR A 143 TYR A 146 1 4 HELIX 10 10 ASP B 20 GLN

B 39 5 20 HELIX 11 11 GLY B 46 THR B 56 1 11 HELIX 12 12 GLY B 66 MET B 68 5

3 HELIX 13 13 GLY B 70 SER B 79 1 10 HELIX 14 14 ASP B 99 VAL B 111 1 13

HELIX 15 15 VAL B 120 ILE B 127 1 8 HELIX 16 16 PRO B 130 ASN B 133 5 4

HELIX 17 17 TYR B 143 ASP B 149 1 7 HELIX 18 18 ASP C 20 ARG C 32 5 13 HELIX

19 19 GLN C 34 GLN C 39 1 6 HELIX 20 20 GLY C 46 THR C 56 5 11 HELIX 21 21

GLY C 66 MET C 68 5 3 HELIX 22 22 GLY C 70 SER C 79 1 10 HELIX 23 23 ASP C

99 VAL C 111 1 13 HELIX 24 24 VAL C 120 ILE C 127 1 8 HELIX 25 25 PRO C 130

ASN C 133 5 4 SHEET 1 A 2 LEU A 3 LEU A 8 0 SHEET 2 A 2 VAL A 136 PRO A

141 -1 N ILE A 140 O THR A 4 SHEET 1 B 5 PRO A 115 ALA A 117 0 SHEET 2 B 5

VAL A 85 PHE A 89 1 N LEU A 86 O PRO A 115 SHEET 3 B 5 HIS A 13 ALA A 18 1 N

ALA A 15 O VAL A 85 SHEET 4 B 5 VAL A 41 THR A 45 1 N VAL A 41 O ILE A 14

SHEET 5 B 5 ASN A 61 MET A 63 1 N ASN A 61 O ALA A 44 SHEET 1 C 2 LEU B 3

LEU B 8 0 SHEET 2 C 2 VAL B 136 PRO B 141 -1 N ILE B 140 O THR B 4 SHEET 1 D

4 VAL B 41 ALA B 44 0 SHEET 2 D 4 HIS B 13 ALA B 18 1 N ILE B 14 O VAL B 41

SHEET 3 D 4 VAL B 85 PHE B 89 1 N VAL B 85 O ALA B 15 SHEET 4 D 4 PRO B 115

ALA B 117 1 N PRO B 115 O LEU B 86 SHEET 1 E 2 LEU C 3 LEU C 8 0 SHEET 2 E 2

VAL C 136 PRO C 141 -1 N ILE C 140 O THR C 4 SHEET 1 F 5 PRO C 115 ALA C 117

0 SHEET 2 F 5 VAL C 85 PHE C 89 1 N LEU C 86 O PRO C 115 SHEET 3 F 5 HIS C

13 ALA C 18 1 N ALA C 15 O VAL C 85 SHEET 4 F 5 VAL C 41 THR C 45 1 N VAL C

41 O ILE C 14 SHEET 5 F 5 VAL C 60 MET C 63 1 N ASN C 61 O LEU C 42 CRYST1

123.340 123.340 155.980 90.00 90.00 120.00 P 65 2 2 36 ORIGX1 1.000000

0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3

0.000000 0.000000 1.000000 0.00000 SCALE1 0.008108 0.004681 0.000000 0.00000

SCALE2 0.000000 0.009362 0.000000 0.00000 SCALE3 0.000000 0.000000 0.006411

0.00000 MTRIX1 1 -0.187058 0.174494 0.966727 -75.20200 1 MTRIX2 1 0.906715

0.409333 0.101561 8.46860 1 MTRIX3 1 -0.377992 0.895543 -0.234785 65.83110 1

Has the ultimate cancer cure arrived?

Hello Folks,

Listmember

pkelly@...

just posted this forward on the medical qi gong list.

It looks like a big breakthrough in cancer therapy.

Green

This is an interesting post from the Cancercure support group.

Have a great weekend.

For those who missed it, here is the news taken from

yesterday's Hindustan Times. My Indian friends tell me that

this is practically the New York Times of India.

====================================================

Has the ultimate cancer cure arrived?

PTI

(Hyderabaad, May 28)

INDIAN CANCER researchers have taken a giant step on the road to

discovering the ultimate cancer cure by developing a drug that

selectively targets the cancer cells without harming the healthy

ones.

Researchers in Kolkata claim that patients in " very advanced stages "

of cancer for whom all other treatments had failed have been brought

back to " excellent " health with the help of a drug formulation they

have developed after research spanning more than a decade.

" We have what we think magic bullet against cancer, " says Manju Ray,

a biochemist at the Indian Association of the Cultivation of Science

(IACS) where the drug was developed under a project funded by the

Department of Science and Technology and the Council of Scientific

and Industrial Research.

Most currently available anti-cancer drugs are toxic because they

also damage the normal cells. Ray says the IACS formulation,

containing " Methylglyoxal " as the lead ingredient, combats only the

diseased cells, the cherished goal of cancer researchers worldwide.

Methylglyoxal is a metabolite in the human body produced during

glucose breakdown.

Others involved in the project are Swapna Ghosh of IACS, Manoj Kar

and Subhankar Ray of the University College of Science, and Santajit

Datta, a medical practitioner. Results of human trial conducted by

them with the new drug have recently appeared in the Indian Journal

of Physics.

While Americans are going ga-ga with their new anti-cancer

drug " Glivec " - that was featured on the cover of May 28 issue of

Time magazine - the low-profile, cash-strapped Kolkata researchers

have been working quietly for over a decade shunning publicity until

they obtained proof from human trials nine weeks ago.

According to their published paper, the Methylglyoxal-based

forumulation had " a dramatic positive effect on the patients " .

For instance, the condition of 11 out of the 19 patients treated -

most of them in a very advanced stage when the treatment began -- are

now stated to be in " excellent physical condition " . Five are in

stable condition and only three died during the course of the study.

Since the submission of the paper, the number of patients treated has

crossed 40 mark with more than 70 per cent success, according to

Manju Ray.

Most remarkable fact, according to the scientists was that

Methylglyoxal was successful against different types of cancer

unlike " Glivec " which targets only the chronic myeloid leukemia.

Those whose health returned to " excellent " condition after treatment

with Methylglyoxal included patients in " a very advanced stages " of

colon cancer, acute myeloid leukemia, non-Hodgkin's lymphoma, and

cancers of ovary, breast, liver, lung, bone, gall bladder, pancreas

and oral cavity.

The patients were inducted for the trial, from January to June 2000,

after obtaining permission from the Drug Controller General of India,

the scientists said. The drug was administered orally for about six

months with gradual reduction of daily dosage from the initial 25

milligrams per kilogram of body weight.

Researchers said development of the drug was preceded by years of

basic research involving human cancer cells in culture and animal

experiments that showed that Methylglyoxal selectively killed the

cancer cells without affecting normal cells by exploiting " a very

significant " biochemical difference between the two.

Explaining the mechanism of action, the scientists said cancer cells

required a large amount of energy providing substance called ATP

(Adenosine-5-Triphosphate) for survival.

" Methylglyoxal inactivates the enzyme (Glyceraldehyde-3- Phosphate

Dehydrogenase) needed for ATP production in cancer cells and thereby

starves them to death. Normal cells remain unaffected. "

Manju ray said that chemists knew Methylglyoxal molecule for about

four decades and its anti-cancer effects in animals had also been

studied. " But surprisingly, no one bothered to initiate further

research leading to human trials, " she said.

The researchers said concern in some quarters about safety of

Methylglyoxal were not borne out from the clinical trials, which

showed that in combination with protective agent like Ascorbic Acid

and vitamins, the drug Methylglyoxal had no major toxic effect. They

said there was scope for further enhancing the drug's efficacy.

Link to comment
Share on other sites
Guest guest

Guest guest

Posted
Posted

And this list classifies Methylglyoxal as a carcinogenic agent (?)

Overall Evaluations of Carcinogenicity to Humans

As evaluated in IARC Monographs Volumes 1-78 (a total of 869 agents,

mixtures and exposures)

This list contains all hazards evaluated to date, according to the type of

hazard posed and to the type of exposure. Where appropriate, chemical

abstract numbers are given [in square brackets]. For details of the

evaluation, the relevant Monograph should be consulted (volume number given

in round brackets, followed by year of publication of latest evaluation).

Use a free-text search to find a particular compound.

Group 1: Carcinogenic to humans (87)

Agents and groups of agents

Aflatoxins, naturally occurring [1402-68-2] (Vol. 56; 1993)

4-Aminobiphenyl [92-67-1] (Vol. 1, Suppl. 7; 1987)

Arsenic [7440-38-2] and arsenic compounds (Vol. 23, Suppl. 7; 1987)

(NB: This evaluation applies to the group of compounds as a whole and not

necessarily to all individual compounds within the group)

Asbestos [1332-21-4] (Vol. 14, Suppl. 7; 1987)

Azathioprine [446-86-6] (Vol. 26, Suppl. 7; 1987)

Benzene [71-43-2] (Vol. 29, Suppl. 7; 1987)

Benzidine [92-87-5] (Vol. 29, Suppl. 7; 1987)

Beryllium [7440-41-7] and beryllium compounds (Vol. 58; 1993)

(NB: Evaluated as a group)

N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornaphazine) [494-03-1] (Vol. 4,

Suppl. 7; 1987)

Bis(chloromethyl)ether [542-88-1] and chloromethyl methyl ether [107-30-2]

(technical-grade)

(Vol. 4, Suppl. 7; 1987)

1,4-Butanediol dimethanesulfonate (Busulphan; Myleran) [55-98-1] (Vol. 4,

Suppl. 7; 1987)

Cadmium [7440-43-9] and cadmium compounds (Vol. 58; 1993)

(NB: Evaluated as a group)

Chlorambucil [305-03-3] (Vol. 26, Suppl. 7; 1987)

1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU;

Semustine) [13909-09-6] (Suppl. 7; 1987)

Chromium[VI] compounds (Vol. 49; 1990)

(NB: Evaluated as a group)

Ciclosporin [79217-60-0] (Vol. 50; 1990)

Cyclophosphamide [50-18-0] [6055-19-2] (Vol. 26, Suppl. 7; 1987)

Diethylstilboestrol [56-53-1] (Vol. 21, Suppl. 7; 1987)

Epstein-Barr virus (Vol. 70; 1997)

Erionite [66733-21-9] (Vol. 42, Suppl. 7; 1987)

Ethylene oxide [75-21-8] (Vol. 60; 1994)

(NB: Overall evaluation upgraded from 2A to 1 with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Etoposide [33419-42-0] in combination with cisplatin and bleomycin (Vol. 76;

2000)

[Gamma Radiation: see X- and Gamma (g)-Radiation]

Helicobacter pylori (infection with) (Vol. 61; 1994)

Hepatitis B virus (chronic infection with) (Vol. 59; 1994)

Hepatitis C virus (chronic infection with) (Vol. 59; 1994)

Human immunodeficiency virus type 1 (infection with) (Vol. 67; 1996)

Human papillomavirus type 16 (Vol. 64; 1995)

Human papillomavirus type 18 (Vol. 64; 1995)

Human T-cell lymphotropic virus type I (Vol. 67; 1996)

Melphalan [148-82-3] (Vol. 9, Suppl. 7; 1987)

8-Methoxypsoralen (Methoxsalen) [298-81-7] plus ultraviolet A radiation

(Vol. 24, Suppl. 7; 1987)

MOPP and other combined chemotherapy including alkylating agents (Suppl. 7;

1987)

Mustard gas (Sulfur mustard) [505-60-2] (Vol. 9, Suppl. 7; 1987)

2-Naphthylamine [91-59-8] (Vol. 4, Suppl. 7; 1987)

Neutrons (Vol. 75; 2000)

Nickel compounds (Vol. 49; 1990)

(NB: Evaluated as a group)

Oestrogen therapy, postmenopausal (Vol. 72; 1999)

Oestrogens, nonsteroidal (Suppl. 7; 1987)

(NB: This evaluation applies to the group of compounds as a whole and not

necessarily to all individual compounds within the group)

Oestrogens, steroidal (Suppl. 7; 1987)

(NB: This evaluation applies to the group of compounds as a whole and not

necessarily to all individual compounds within the group)

Opisthorchis viverrini (infection with) (Vol. 61; 1994)

Oral contraceptives, combined (Vol. 72; 1999)

(NB: There is also conclusive evidence that these agents have a protective

effect against cancers of the ovary and endometrium)

Oral contraceptives, sequential (Suppl. 7; 1987)

Phosphorus-32, as phosphate (Vol. 78; 2001)

Plutonium-239 and its decay products (may contain plutonium-240 and other

isotopes), as aerosols (Vol. 78; 2001)

Radioiodines, short-lived isotopes, including iodine-131, from atomic

reactor accidents and nuclear weapons detonation (exposure during childhood)

(Vol. 78; 2001)

Radionuclides, a-particle-emitting, internally deposited (Vol. 78; 2001)

(NB: Specific radionuclides for which there is sufficient evidence for

carcinogenicity to humans are also listed individually as Group 1 agents)

Radionuclides, b-particle-emitting, internally deposited (Vol. 78; 2001)

(NB: Specific radionuclides for which there is sufficient evidence for

carcinogenicity to humans are also listed individually as Group 1 agents)

Radium-224 and its decay products (Vol. 78; 2001)

Radium-226 and its decay products (Vol. 78; 2001)

Radium-228 and its decay products (Vol. 78; 2001)

Radon-222 [10043-92-2] and its decay products (Vol. 78; 2001)

Schistosoma haematobium (infection with) (Vol. 61; 1994)

Silica [14808-60-7], crystalline (inhaled in the form of quartz or

cristobalite from occupational sources) (Vol. 68; 1997)

Solar radiation (Vol. 55; 1992)

Talc containing asbestiform fibres (Vol. 42, Suppl. 7; 1987)

Tamoxifen [10540-29-1] (Vol. 66; 1996)

(NB: There is also conclusive evidence that this agent (tamoxifen) reduces

the risk of contralateral breast cancer)

2,3,7,8-Tetrachlorodibenzo-para-dioxin [1746-01-6] (Vol. 69; 1997)

(NB: Overall evaluation upgraded from 2A to 1 with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Thiotepa [52-24-4] (Vol. 50; 1990)

Thorium-232 and its decay products, administered intravenously as a

colloidal dispersion of thorium-232 dioxide (Vol. 78; 2001)

Treosulfan [299-75-2] (Vol. 26, Suppl. 7; 1987)

Vinyl chloride [75-01-4] (Vol. 19, Suppl. 7; 1987)

X- and Gamma (g)-Radiation (Vol. 75; 2000)

Mixtures

Alcoholic beverages (Vol. 44; 1988)

Analgesic mixtures containing phenacetin (Suppl. 7; 1987)

Betel quid with tobacco (Vol. 37, Suppl. 7; 1987)

Coal-tar pitches [65996-93-2] (Vol. 35, Suppl. 7; 1987)

Coal-tars [8007-45-2] (Vol. 35, Suppl. 7; 1987)

Mineral oils, untreated and mildly treated (Vol. 33, Suppl. 7; 1987)

Salted fish (Chinese-style) (Vol. 56; 1993)

Shale-oils [68308-34-9] (Vol. 35, Suppl. 7; 1987)

Soots (Vol. 35, Suppl. 7; 1987)

Tobacco products, smokeless (Vol. 37, Suppl. 7; 1987)

Tobacco smoke (Vol. 38, Suppl. 7; 1987)

Wood dust (Vol. 62; 1995)

Exposure circumstances

Aluminium production (Vol. 34, Suppl. 7; 1987)

Auramine, manufacture of (Suppl. 7; 1987)

Boot and shoe manufacture and repair (Vol. 25, Suppl. 7; 1987)

Coal gasification (Vol. 34, Suppl. 7; 1987)

Coke production (Vol. 34, Suppl. 7; 1987)

Furniture and cabinet making (Vol. 25, Suppl. 7; 1987)

Haematite mining (underground) with exposure to radon (Vol. 1, Suppl. 7;

1987)

Iron and steel founding (Vol. 34, Suppl. 7; 1987)

Isopropanol manufacture (strong-acid process) (Suppl. 7; 1987)

Magenta, manufacture of (Vol. 57; 1993)

Painter (occupational exposure as a) (Vol. 47; 1989)

Rubber industry (Vol. 28, Suppl. 7; 1987)

Strong-inorganic-acid mists containing sulfuric acid (occupational exposure

to) (Vol. 54; 1992)

Group 2A: Probably carcinogenic to humans (63)

Agents and groups of agents

Acrylamide [79-06-1] (Vol. 60; 1994)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Adriamycin [23214-92-8] (Vol. 10, Suppl. 7; 1987)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Androgenic (anabolic) steroids (Suppl. 7; 1987)

Azacitidine [320-67-2] (Vol. 50; 1990)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Benz[a]anthracene [56-55-3] (Vol. 32, Suppl. 7; 1987)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Benzidine-based dyes (Suppl. 7; 1987)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Benzo[a]pyrene [50-32-8] (Vol. 32, Suppl. 7; 1987)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Bischloroethyl nitrosourea (BCNU) [154-93-8] (Vol. 26, Suppl. 7; 1987)

1,3-Butadiene [106-99-0] (Vol. 71; 1999)

Captafol [2425-06-1] (Vol. 53; 1991)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Chloramphenicol [56-75-7] (Vol. 50; 1990)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

a-Chlorinated toluenes (benzal chloride [98-87-3], benzotrichloride

[98-07-7], benzyl chloride [100-44-7]) and benzoyl chloride [98-88-4]

(combined exposures) (Vol. 29, Suppl. 7, Vol. 71; 1999)

1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) [13010-47-4] (Vol. 26,

Suppl. 7; 1987)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

para-Chloro-ortho-toluidine [95-69-2] and its strong acid salts (Vol. 48,

Vol. 77; 2000)

(NB: Evaluated as a group)

Chlorozotocin [54749-90-5] (Vol. 50; 1990)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Cisplatin [15663-27-1] (Vol. 26, Suppl. 7; 1987)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Clonorchis sinensis (infection with) (Vol. 61; 1994)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Dibenz[a,h]anthracene [53-70-3] (Vol. 32, Suppl. 7; 1987)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Diethyl sulfate [64-67-5] (Vol. 54, Vol. 71; 1999)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Dimethylcarbamoyl chloride [79-44-7] (Vol. 12, Suppl. 7, Vol. 71; 1999)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

1,2-Dimethylhydrazine [540-73-8] (Vol. 4, Suppl. 7, Vol. 71; 1999)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Dimethyl sulfate [77-78-1] (Vol. 4, Suppl. 7, Vol. 71; 1999)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Epichlorohydrin [106-89-8] (Vol. 11, Suppl. 7, Vol. 71; 1999)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Ethylene dibromide [106-93-4] (Vol. 15, Suppl. 7, Vol. 71; 1999)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

N-Ethyl-N-nitrosourea [759-73-9] (Vol. 17, Suppl. 7; 1987)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Etoposide [33419-42-0] (Vol. 76; 2000)

(NB: Other relevant data taken into consideration in making the overall

evaluation)

Formaldehyde [50-00-0] (Vol. 62; 1995)

Glycidol [556-52-5] (Vol. 77; 2000)

(NB: Other relevant data taken into consideration in making the overall

evaluation)

Human papillomavirus type 31 (Vol. 64; 1995)

Human papillomavirus type 33 (Vol. 64; 1995)

IQ (2-Amino-3-methylimidazo[4,5-f]quinoline) [76180-96-6] (Vol. 56; 1993)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Kaposi's sarcoma herpesvirus/human herpesvirus 8 (Vol. 70; 1997)

5-Methoxypsoralen [484-20-8] (Vol. 40, Suppl. 7; 1987)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

4,4?-Methylene bis(2-chloroaniline) (MOCA) [101-14-4] (Vol. 57; 1993)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Methyl methanesulfonate [66-27-3] (Vol. 7, Suppl. 7, Vol. 71; 1999)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

N-Methyl-N?-nitro-N-nitrosoguanidine (MNNG) [70-25-7] (Vol. 4, Suppl. 7;

1987)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

N-Methyl-N-nitrosourea [684-93-5] (Vol. 17, Suppl. 7; 1987)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Nitrogen mustard [51-75-2] (Vol. 9, Suppl. 7; 1987)

N-Nitrosodiethylamine [55-18-5] (Vol. 17, Suppl. 7; 1987)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

N-Nitrosodimethylamine [62-75-9] (Vol. 17, Suppl. 7; 1987)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Phenacetin [62-44-2] (Vol. 24, Suppl. 7; 1987)

Procarbazine hydrochloride [366-70-1] (Vol. 26, Suppl. 7; 1987)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Styrene-7,8-oxide [96-09-3] (Vol. 60; 1994)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Teniposide [29767-20-2] (Vol. 76; 2000)

(NB: Other relevant data taken into consideration in making the overall

evaluation)

Tetrachloroethylene [127-18-4] (Vol. 63; 1995)

ortho-Toluidine [95-53-4] (Vol. 27, Suppl. 7, Vol. 77; 2000)

Trichloroethylene [79-01-6] (Vol. 63; 1995)

1,2,3-Trichloropropane [96-18-4] (Vol. 63; 1995)

Tris(2,3-dibromopropyl) phosphate [126-72-7] (Vol. 20, Suppl. 7, Vol. 71;

1999)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Ultraviolet radiation A (Vol. 55; 1992)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Ultraviolet radiation B (Vol. 55; 1992)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Ultraviolet radiation C (Vol. 55; 1992)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Vinyl bromide [593-60-2] (Vol. 39, Suppl. 7, Vol. 71; 1999)

(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Vinyl fluoride [75-02-5] (Vol. 63; 1995)

Mixtures

Creosotes [8001-58-9] (Vol. 35, Suppl. 7; 1987)

Diesel engine exhaust (Vol. 46; 1989)

Hot mate (Vol. 51; 1991)

Non-arsenical insecticides (occupational exposures in spraying and

application of) (Vol. 53; 1991)

Polychlorinated biphenyls [1336-36-3] (Vol. 18, Suppl. 7; 1987)

Exposure circumstances

Art glass, glass containers and pressed ware (manufacture of) (Vol. 58;

1993)

Hairdresser or barber (occupational exposure as a) (Vol. 57; 1993)

Petroleum refining (occupational exposures in) (Vol. 45; 1989)

Sunlamps and sunbeds (use of) (Vol. 55; 1992)

Group 2B: Possibly carcinogenic to humans (235)

Agents and groups of agents

A-a-C (2-Amino-9H-pyrido[2,3-b]indole) [26148-68-5] (Vol. 40, Suppl. 7;

1987)

Acetaldehyde [75-07-0] (Vol. 36, Suppl. 7, Vol. 71; 1999)

Acetamide [60-35-5] (Vol. 7, Suppl. 7, Vol. 71; 1999)

Acrylonitrile [107-13-1] (Vol. 71; 1999)

AF-2 [2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide] [3688-53-7] (Vol. 31,

Suppl. 7; 1987)

Aflatoxin M1 [6795-23-9] (Vol. 56; 1993)

para-Aminoazobenzene [60-09-3] (Vol. 8, Suppl. 7; 1987)

ortho-Aminoazotoluene [97-56-3] (Vol. 8, Suppl. 7; 1987)

2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole [712-68-5] (Vol. 7, Suppl. 7;

1987)

Amitrole [61-82-5] (Vol. 41, Suppl. 7; 1987)

Amsacrine [51264-14-3] (Vol. 76; 2000)

ortho-Anisidine [90-04-0] (Vol. 73; 1999)

Antimony trioxide [1309-64-4] (Vol. 47; 1989)

AramiteR [140-57-8] (Vol. 5, Suppl. 7; 1987)

Auramine [492-80-8] (technical-grade) (Vol. 1, Suppl. 7; 1987)

Azaserine [115-02-6] (Vol. 10, Suppl. 7; 1987)

Aziridine [151-56-4] (Vol. 9, Suppl. 7, Vol. 71; 1999)

(NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Benzofluoranthene [205-99-2] (Vol. 32, Suppl. 7; 1987)

Benzo[j]fluoranthene [205-82-3] (Vol. 32, Suppl. 7; 1987)

Benzo[k]fluoranthene [207-08-9] (Vol. 32, Suppl. 7; 1987)

Benzofuran [271-89-6] (Vol. 63; 1995)

Benzyl violet 4B [1694-09-3] (Vol. 16, Suppl. 7; 1987)

2,2-Bis(bromomethyl)propane-1,3-diol [3296-90-0] (Vol. 77; 2000)

Bleomycins [11056-06-7] (Vol. 26, Suppl. 7; 1987)

(NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Bracken fern (Vol. 40, Suppl. 7; 1987)

Bromodichloromethane [75-27-4] (Vol. 52, Vol. 71; 1999)

Butylated hydroxyanisole (BHA) [25013-16-5] (Vol. 40, Suppl. 7; 1987)

b-Butyrolactone [3068-88-0] (Vol. 11, Suppl. 7, Vol. 71; 1999)

Caffeic acid [331-39-5] (Vol. 56; 1993)

Carbon black [1333-86-4] (Vol. 65; 1996)

Carbon tetrachloride [56-23-5] (Vol. 20, Suppl. 7, Vol. 71; 1999)

Catechol [120-80-9] (Vol. 15, Suppl. 7, Vol. 71; 1999)

Ceramic fibres (Vol. 43; 1988)

Chlordane [57-74-9] (Vol. 53; 1991)

Chlordecone (Kepone) [143-50-0] (Vol. 20, Suppl. 7; 1987)

Chlorendic acid [115-28-6] (Vol. 48; 1990)

para-Chloroaniline [106-47-8] (Vol. 57; 1993)

Chloroform [67-66-3] (Vol. 73; 1999)

1-Chloro-2-methylpropene [513-37-1] (Vol. 63; 1995)

Chlorophenoxy herbicides (Vol. 41, Suppl. 7; 1987)

4-Chloro-ortho-phenylenediamine [95-83-0] (Vol. 27, Suppl. 7; 1987)

Chloroprene [126-99-8] (Vol. 71; 1999)

Chlorothalonil [1897-45-6] (Vol. 73; 1999)

CI Acid Red 114 [6459-94-5] (Vol. 57; 1993)

CI Basic Red 9 [569-61-9] (Vol. 57; 1993)

CI Direct Blue 15 [2429-74-5] (Vol. 57; 1993)

Citrus Red No. 2 [6358-53-8] (Vol. 8, Suppl. 7; 1987)

Cobalt [7440-48-4] and cobalt compounds (Vol. 52; 1991)

(NB: Evaluated as a group)

para-Cresidine [120-71-8] (Vol. 27, Suppl. 7; 1987)

Cycasin [14901-08-7] (Vol. 10, Suppl. 7; 1987)

Dacarbazine [4342-03-4] (Vol. 26, Suppl. 7; 1987)

Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone) [117-10-2] (Vol. 50; 1990)

Daunomycin [20830-81-3] (Vol. 10, Suppl. 7; 1987)

DDT [p,p'-DDT, 50-29-3] (Vol. 53; 1991)

N,N'-Diacetylbenzidine [613-35-4] (Vol. 16, Suppl. 7; 1987)

2,4-Diaminoanisole [615-05-4] (Vol. 27, Suppl. 7; 1987)

4,4'-Diaminodiphenyl ether [101-80-4] (Vol. 29, Suppl. 7; 1987)

2,4-Diaminotoluene [95-80-7] (Vol. 16, Suppl. 7; 1987)

Dibenz[a,h]acridine [226-36-8] (Vol. 32, Suppl. 7; 1987)

Dibenz[a,j]acridine [224-42-0] (Vol. 32, Suppl. 7; 1987)

7H-Dibenzo[c,g]carbazole [194-59-2] (Vol. 32, Suppl. 7; 1987)

Dibenzo[a,e]pyrene [192-65-4] (Vol. 32, Suppl. 7; 1987)

Dibenzo[a,h]pyrene [189-64-0] (Vol. 32, Suppl. 7; 1987)

Dibenzo[a,i]pyrene [189-55-9] (Vol. 32, Suppl. 7; 1987)

Dibenzo[a,l]pyrene [191-30-0] (Vol. 32, Suppl. 7; 1987)

1,2-Dibromo-3-chloropropane [96-12-8] (Vol. 20, Suppl. 7, Vol. 71; 1999)

2,3-Dibromopropan-1-ol [96-13-9] (Vol. 77; 2000)

para-Dichlorobenzene [106-46-7] (Vol. 73; 1999)

3,3'-Dichlorobenzidine [91-94-1] (Vol. 29, Suppl. 7; 1987)

3,3'-Dichloro-4,4'-diaminodiphenyl ether [28434-86-8] (Vol. 16, Suppl. 7;

1987)

1,2-Dichloroethane [107-06-2] (Vol. 20, Suppl. 7, Vol. 71; 1999)

Dichloromethane (methylene chloride) [75-09-2] (Vol. 71; 1999)

1,3-Dichloropropene [542-75-6] (technical-grade) (Vol. 41, Suppl. 7, Vol.

71; 1999)

Dichlorvos [62-73-7] (Vol. 53; 1991)

1,2-Diethylhydrazine [1615-80-1] (Vol. 4, Suppl. 7, Vol. 71; 1999)

Diglycidyl resorcinol ether [101-90-6] (Vol. 36, Suppl. 7, Vol. 71; 1999)

Dihydrosafrole [94-58-6] (Vol. 10, Suppl. 7; 1987)

Diisopropyl sulfate [2973-10-6] (Vol. 54, Vol. 71; 1999)

3,3'-Dimethoxybenzidine (ortho-Dianisidine) [119-90-4] (Vol. 4, Suppl. 7;

1987)

para-Dimethylaminoazobenzene [60-11-7] (Vol. 8, Suppl. 7; 1987)

trans-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)-vinyl]-1,3,4-oxa

diazole [25962-77-0]

(Vol. 7, Suppl. 7; 1987)

2,6-Dimethylaniline (2,6-Xylidine) [87-62-7] (Vol. 57; 1993)

3,3'-Dimethylbenzidine (ortho-Tolidine) [119-93-7] (Vol. 1, Suppl. 7; 1987)

1,1-Dimethylhydrazine [57-14-7] (Vol. 4, Suppl. 7, Vol. 71; 1999)

3,7-Dinitrofluoranthene [105735-71-5] (Vol. 65; 1996)

3,9-Dinitrofluoranthene [22506-53-2] (Vol. 65; 1996)

1,6-Dinitropyrene [42397-64-8] (Vol. 46; 1989)

1,8-Dinitropyrene [42397-65-9] (Vol. 46; 1989)

2,4-Dinitrotoluene [121-14-2] (Vol. 65; 1996)

2,6-Dinitrotoluene [606-20-2] (Vol. 65; 1996)

1,4-Dioxane [123-91-1] (Vol. 11, Suppl. 7, Vol. 71; 1999)

Disperse Blue 1 [2475-45-8] (Vol. 48; 1990)

1,2-Epoxybutane [106-88-7] (Vol. 47, Vol. 71; 1999)

(NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Ethyl acrylate [140-88-5] (Vol. 39, Suppl. 7, Vol. 71; 1999)

Ethylbenzene [100-41-4] (Vol. 77; 2000)

Ethylene thiourea [96-45-7] (Vol. 7, Suppl. 7; 1987)

Ethyl methanesulfonate [62-50-0] (Vol. 7, Suppl. 7; 1987)

Foreign bodies, implanted in tissues (Vol. 74; 1999)

Polymeric, prepared as thin smooth films (with the exception of

poly(glycolic acid))

Metallic, prepared as thin smooth films

Metallic cobalt, metallic nickel and an alloy powder containing 66-67%

nickel, 13-16% chromium and 7% iron

2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole [3570-75-0] (Vol. 7,

Suppl. 7; 1987)

Furan [110-00-9] (Vol. 63; 1995)

Glasswool (Vol. 43; 1988)

Glu-P-1 (2-Amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole) [67730-11-4]

(Vol. 40, Suppl. 7; 1987)

Glu-P-2 (2-Aminodipyrido[1,2-a:3',2'-d]imidazole) [67730-10-3] (Vol. 40,

Suppl. 7; 1987)

Glycidaldehyde [765-34-4] (Vol. 11, Suppl. 7, Vol. 71; 1999)

Griseofulvin [126-07-8] (Vol. 10, Suppl. 7; 1987)

HC Blue No. 1 [2784-94-3] (Vol. 57; 1993)

Heptachlor [76-44-8] (Vol. 53; 1991)

Hexachlorobenzene [118-74-1] (Vol. 20, Suppl. 7; 1987)

Hexachloroethane [67-72-1] (Vol. 73; 1999)

Hexachlorocyclohexanes (Vol. 20, Suppl. 7; 1987)

Hexamethylphosphoramide [680-31-9] (Vol. 15, Suppl. 7, Vol. 71; 1999)

Human immunodeficiency virus type 2 (infection with) (Vol. 67; 1996)

Human papillomaviruses: some types other than 16, 18, 31 and 33 (Vol. 64;

1995)

Hydrazine [302-01-2] (Vol. 4, Suppl. 7, Vol. 71; 1999)

Indeno[1,2,3-cd]pyrene [193-39-5] (Vol. 32, Suppl. 7; 1987)

Iron-dextran complex [9004-66-4] (Vol. 2, Suppl. 7; 1987)

Isoprene [78-79-5] (Vol. 60, Vol. 71; 1999)

Lasiocarpine [303-34-4] (Vol. 10, Suppl. 7; 1987)

Lead [7439-92-1] and lead compounds, inorganic (Vol. 23, Suppl. 7; 1987)

(NB: Evaluated as a group)

Magenta [632-99-5] (containing CI Basic Red 9) (Vol. 57; 1993)

MeA-a-C (2-Amino-3-methyl-9H-pyrido[2,3-b]indole) [68006-83-7] (Vol. 40,

Suppl. 7; 1987)

Medroxyprogesterone acetate [71-58-9] (Vol. 21, Suppl. 7; 1987)

MeIQ (2-Amino-3,4-dimethylimidazo[4,5-f]quinoline) [77094-11-2] (Vol. 56;

1993)

MeIQx (2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline) [77500-04-0] (Vol. 56;

1993)

Merphalan [531-76-0] (Vol. 9, Suppl. 7; 1987)

2-Methylaziridine (Propyleneimine) [75-55-8] (Vol. 9, Suppl. 7, Vol. 71;

1999)

Methylazoxymethanol acetate [592-62-1] (Vol. 10, Suppl. 7; 1987)

5-Methylchrysene [3697-24-3] (Vol. 32, Suppl. 7; 1987)

4,4'-Methylene bis(2-methylaniline) [838-88-0] (Vol. 4, Suppl. 7; 1987)

4,4'-Methylenedianiline [101-77-9] (Vol. 39, Suppl. 7; 1987)

Methylmercury compounds (Vol. 58; 1993)

(NB: Evaluated as a group)

2-Methyl-1-nitroanthraquinone [129-15-7] (uncertain purity) (Vol. 27, Suppl.

7; 1987)

N-Methyl-N-nitrosourethane [615-53-2] (Vol. 4, Suppl. 7; 1987)

Methylthiouracil [56-04-2] (Vol. 7, Suppl. 7; 1987)

Metronidazole [443-48-1] (Vol. 13, Suppl. 7; 1987)

Mirex [2385-85-5] (Vol. 20, Suppl. 7; 1987)

Mitomycin C [50-07-7] (Vol. 10, Suppl. 7; 1987)

Mitoxantrone [65271-80-9] (Vol. 76; 2000)

Monocrotaline [315-22-0] (Vol. 10, Suppl. 7; 1987)

5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone

[3795-88-8] (Vol. 7, Suppl. 7; 1987)

Nafenopin [3771-19-5] (Vol. 24, Suppl. 7; 1987)

Nickel, metallic [7440-02-0] and alloys (Vol. 49; 1990)

Niridazole [61-57-4] (Vol. 13, Suppl. 7; 1987)

Nitrilotriacetic acid [139-13-9] and its salts (Vol. 73; 1999)

(NB: Evaluated as a group)

5-Nitroacenaphthene [602-87-9] (Vol. 16, Suppl. 7; 1987)

2-Nitroanisole [91-23-6] (Vol. 65; 1996)

Nitrobenzene [98-95-3] (Vol. 65; 1996)

6-Nitrochrysene [7496-02-8] (Vol. 46; 1989)

Nitrofen [1836-75-5] (technical-grade) (Vol. 30, Suppl. 7; 1987)

2-Nitrofluorene [607-57-8] (Vol. 46; 1989)

1-[(5-Nitrofurfurylidene)amino]-2-imidazolidinone [555-84-0] (Vol. 7, Suppl.

7; 1987)

N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide [531-82-8] (Vol. 7, Suppl. 7;

1987)

Nitrogen mustard N-oxide [126-85-2] (Vol. 9, Suppl. 7; 1987)

Nitromethane [75-52-5] (Vol. 77; 2000)

2-Nitropropane [79-46-9] (Vol. 29, Suppl. 7, Vol. 71; 1999)

1-Nitropyrene [5522-43-0] (Vol. 46; 1989)

4-Nitropyrene [57835-92-4] (Vol. 46; 1989)

N-Nitrosodi-n-butylamine [924-16-3] (Vol. 17, Suppl. 7; 1987)

N-Nitrosodiethanolamine [1116-54-7] (Vol. 17, Suppl. 7, Vol. 77; 2000)

N-Nitrosodi-n-propylamine [621-64-7] (Vol. 17, Suppl. 7; 1987)

3-(N-Nitrosomethylamino)propionitrile [60153-49-3] (Vol. 37, Suppl. 7; 1987)

4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) [64091-91-4] (Vol.

37, Suppl. 7; 1987)

N-Nitrosomethylethylamine [10595-95-6] (Vol. 17, Suppl. 7; 1987)

N-Nitrosomethylvinylamine [4549-40-0] (Vol. 17, Suppl. 7; 1987)

N-Nitrosomorpholine [59-89-2] (Vol. 17, Suppl. 7; 1987)

N'-Nitrosonornicotine [16543-55-8] (Vol. 37, Suppl. 7; 1987)

N-Nitrosopiperidine [100-75-4] (Vol. 17, Suppl. 7; 1987)

N-Nitrosopyrrolidine [930-55-2] (Vol. 17, Suppl. 7; 1987)

N-Nitrososarcosine [13256-22-9] (Vol. 17, Suppl. 7; 1987)

Ochratoxin A [303-47-9] (Vol. 56; 1993)

Oestrogen-progestogen therapy, postmenopausal (Vol. 72; 1999)

Oil Orange SS [2646-17-5] (Vol. 8, Suppl. 7; 1987)

Oxazepam [604-75-1] (Vol. 66; 1996)

Palygorskite (attapulgite) [12174-11-7] (long fibres, > 5 micrometers) (Vol.

68; 1997)

Panfuran S [794-93-4] (containing dihydroxymethylfuratrizine)

(Vol. 24, Suppl. 7; 1987)

Phenazopyridine hydrochloride [136-40-3] (Vol. 24, Suppl. 7; 1987)

Phenobarbital [50-06-6] (Vol. 13, Suppl. 7; 1987)

Phenolphthalein [77-09-8] (Vol. 76; 2000)

Phenoxybenzamine hydrochloride [63-92-3] (Vol. 24, Suppl. 7; 1987)

Phenyl glycidyl ether [122-60-1] (Vol. 47, Vol. 71; 1999)

Phenytoin [57-41-0] (Vol. 66; 1996)

PhIP (2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) [105650-23-5] (Vol.

56; 1993)

Polychlorophenols and their sodium salts (mixed exposures) (Vol. 41, Suppl.

7, Vol. 53, Vol. 71; 1999)

Ponceau MX [3761-53-3] (Vol. 8, Suppl. 7; 1987)

Ponceau 3R [3564-09-8] (Vol. 8, Suppl. 7; 1987)

Potassium bromate [7758-01-2] (Vol. 73; 1999)

Progestins (Suppl. 7; 1987)

Progestogen-only contraceptives (Vol. 72; 1999)

1,3-Propane sultone [1120-71-4] (Vol. 4, Suppl. 7, Vol. 71; 1999)

b-Propiolactone [57-57-8] (Vol. 4, Suppl. 7, Vol. 71; 1999)

Propylene oxide [75-56-9] (Vol. 60; 1994)

Propylthiouracil [51-52-5] (Vol. 7, Suppl. 7; 1987)

Rockwool (Vol. 43; 1988)

Safrole [94-59-7] (Vol. 10, Suppl. 7; 1987)

Schistosoma japonicum (infection with) (Vol. 61; 1994)

Slagwool (Vol. 43; 1988)

Sodium ortho-phenylphenate [132-27-4] (Vol. 73; 1999)

Sterigmatocystin [10048-13-2] (Vol. 10, Suppl. 7; 1987)

Streptozotocin [18883-66-4] (Vol. 17, Suppl. 7; 1987)

Styrene [100-42-5] (Vol. 60; 1994)

(NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Sulfallate [95-06-7] (Vol. 30, Suppl. 7; 1987)

Tetrafluoroethylene [116-14-3] (Vol. 19, Suppl. 7, Vol. 71; 1999)

Tetranitromethane [509-14-8] (Vol. 65; 1996)

Thioacetamide [62-55-5] (Vol. 7, Suppl. 7; 1987)

4,4'-Thiodianiline [139-65-1] (Vol. 27, Suppl. 7; 1987)

Thiourea [62-56-6] (Vol. 7, Suppl. 7; 1987)

Toluene diisocyanates [26471-62-5] (Vol. 39, Suppl. 7, Vol. 71; 1999)

Toxins derived from Fusarium moniliforme (Vol. 56; 1993)

Trichlormethine (Trimustine hydrochloride) [817-09-4] (Vol. 50; 1990)

Trp-P-1 (3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole) [62450-06-0] (Vol. 31,

Suppl. 7; 1987)

Trp-P-2 (3-Amino-1-methyl-5H-pyrido[4,3-b]indole) [62450-07-1] (Vol. 31,

Suppl. 7; 1987)

Trypan blue [72-57-1] (Vol. 8, Suppl. 7; 1987)

Uracil mustard [66-75-1] (Vol. 9, Suppl. 7; 1987)

Urethane [51-79-6] (Vol. 7, Suppl. 7; 1987)

Vinyl acetate [108-05-4] (Vol. 63; 1995)

4-Vinylcyclohexene [100-40-3] (Vol. 60; 1994)

4-Vinylcyclohexene diepoxide [106-87-6] (Vol. 60; 1994)

Zalcitabine [7481-89-2] (Vol. 76; 2000)

Zidovudine (AZT) [30516-87-1] (Vol. 76; 2000)

Mixtures

Bitumens [8052-42-4], extracts of steam-refined and air-refined (Vol. 35,

Suppl. 7; 1987)

Carrageenan [9000-07-1], degraded (Vol. 31, Suppl. 7; 1987)

Chlorinated paraffins of average carbon chain length C12 and average degree

of chlorination approximately 60% (Vol. 48; 1990)

Coffee (urinary bladder) (Vol. 51; 1991)

(NB: There is some evidence of an inverse relationship between coffee

drinking and cancer of the large bowel; coffee drinking could not be

classified as to its carcinogenicity to other organs)

Diesel fuel, marine (Vol. 45; 1989)

(NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Engine exhaust, gasoline (Vol. 46; 1989)

Fuel oils, residual (heavy) (Vol. 45; 1989)

Gasoline (Vol. 45; 1989)

(NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from

other data relevant to the evaluation of carcinogenicity and its mechanisms)

Pickled vegetables (traditional in Asia) (Vol. 56; 1993)

Polybrominated biphenyls [Firemaster BP-6, 59536-65-1] (Vol. 41, Suppl. 7;

1987)

Toxaphene (Polychlorinated camphenes) [8001-35-2] (Vol. 20, Suppl. 7; 1987)

Welding fumes (Vol. 49; 1990)

Exposure circumstances

Carpentry and joinery (Vol. 25, Suppl. 7; 1987)

Dry cleaning (occupational exposures in) (Vol. 63; 1995)

Printing processes (occupational exposures in) (Vol. 65; 1996)

Textile manufacturing industry (work in) (Vol. 48; 1990)

Group 3: Unclassifiable as to carcinogenicity to humans (483)

Agents and groups of agents

Aciclovir [59277-89-3] (Vol. 76; 2000)

Acridine orange [494-38-2] (Vol. 16, Suppl. 7; 1987)

Acriflavinium chloride [8018-07-3] (Vol. 13, Suppl. 7; 1987)

Acrolein [107-02-8] (Vol. 63; 1995)

Acrylic acid [79-10-7] (Vol. 19, Suppl. 7, Vol. 71; 1999)

Acrylic fibres (Vol. 19, Suppl. 7; 1987)

Acrylonitrile-butadiene-styrene copolymers (Vol. 19, Suppl. 7; 1987)

Actinomycin D [50-76-0] (Vol. 10, Suppl. 7; 1987)

Agaritine [2757-90-6] (Vol. 31, Suppl. 7; 1987)

Aldicarb [116-06-3] (Vol. 53; 1991)

Aldrin [309-00-2] (Vol. 5, Suppl. 7; 1987)

Allyl chloride [107-05-1] (Vol. 36, Suppl. 7, Vol. 71; 1999)

Allyl isothiocyanate [57-06-7] (Vol. 73; 1999)

Allyl isovalerate [2835-39-4] (Vol. 36, Suppl. 7, Vol. 71; 1999)

Amaranth [915-67-3] (Vol. 8, Suppl. 7; 1987)

5-Aminoacenaphthene [4657-93-6] (Vol. 16, Suppl. 7; 1987)

2-Aminoanthraquinone [117-79-3] (Vol. 27, Suppl. 7; 1987)

para-Aminobenzoic acid [150-13-0] (Vol. 16, Suppl. 7; 1987)

1-Amino-2-methylanthraquinone [82-28-0] (Vol. 27, Suppl. 7; 1987)

2-Amino-4-nitrophenol [99-57-0] (Vol. 57; 1993)

2-Amino-5-nitrophenol [121-88-0] (Vol. 57; 1993)

4-Amino-2-nitrophenol [119-34-6] (Vol. 16, Suppl. 7; 1987)

2-Amino-5-nitrothiazole [121-66-4] (Vol. 31, Suppl. 7; 1987)

11-Aminoundecanoic acid [2432-99-7] (Vol. 39, Suppl. 7; 1987)

Ampicillin [69-53-4] (Vol. 50; 1990)

Anaesthetics, volatile (Vol. 11, Suppl. 7; 1987)

Angelicin [523-50-2] plus ultraviolet A radiation (Vol. 40, Suppl. 7; 1987)

Aniline [62-53-3] (Vol. 27, Suppl. 7; 1987)

para-Anisidine [104-94-9] (Vol. 27, Suppl. 7; 1987)

Anthanthrene [191-26-4] (Vol. 32, Suppl. 7; 1987)

Anthracene [120-12-7] (Vol. 32, Suppl. 7; 1987)

Anthranilic acid [118-92-3] (Vol. 16, Suppl. 7; 1987)

Antimony trisulfide [1345-04-6] (Vol. 47; 1989)

Apholate [52-46-0] (Vol. 9, Suppl. 7; 1987)

para-Aramid fibrils [24938-64-5] (Vol. 68; 1997)

Atrazine [1912-24-9] (Vol. 73; 1999)

(NB: Overall evaluation downgraded from 2B to 3 with supporting evidence

from other data relevant to carcinogenicity and its mechanisms)

Aurothioglucose [12192-57-3] (Vol. 13, Suppl. 7; 1987)

2-(1-Aziridinyl)ethanol [1072-52-2] (Vol. 9, Suppl. 7; 1987)

Aziridyl benzoquinone [800-24-8] (Vol. 9, Suppl. 7; 1987)

Azobenzene [103-33-3] (Vol. 8, Suppl. 7; 1987)

Benz[a]acridine [225-11-6] (Vol. 32, Suppl. 7; 1987)

Benz[c]acridine [225-51-4] (Vol. 32, Suppl. 7; 1987)

Benzo[ghi]fluoranthene [203-12-3] (Vol. 32, Suppl. 7; 1987)

Benzo[a]fluorene [238-84-6] (Vol. 32, Suppl. 7; 1987)

Benzofluorene [243-17-4] (Vol. 32, Suppl. 7; 1987)

Benzo[c]fluorene [205-12-9] (Vol. 32, Suppl. 7; 1987)

Benzo[ghi]perylene [191-24-2] (Vol. 32, Suppl. 7; 1987)

Benzo[c]phenanthrene [195-19-7] (Vol. 32, Suppl. 7; 1987)

Benzo[e]pyrene [192-97-2] (Vol. 32, Suppl. 7; 1987)

para-Benzoquinone dioxime [105-11-3] (Vol. 29, Suppl. 7, Vol. 71; 1999)

Benzoyl peroxide [94-36-0] (Vol. 36, Suppl. 7, Vol. 71; 1999)

Benzyl acetate [140-11-4] (Vol. 40, Suppl. 7, Vol. 71; 1999)

Bis(1-aziridinyl)morpholinophosphine sulfide [2168-68-5] (Vol. 9, Suppl. 7;

1987)

Bis(2-chloroethyl)ether [111-44-4] (Vol. 9, Suppl. 7, Vol. 71; 1999)

1,2-Bis(chloromethoxy)ethane [13483-18-6] (Vol. 15; Suppl. 7, Vol. 71; 1999)

1,4-Bis(chloromethoxymethyl)benzene [56894-91-8] (Vol. 15, Suppl. 7, Vol.

71; 1999)

Bis(2-chloro-1-methylethyl)ether [108-60-1] (Vol. 41, Suppl. 7, Vol. 71;

1999)

Bis(2,3-epoxycyclopentyl)ether [2386-90-5] (Vol. 47, Vol. 71; 1999)

Bisphenol A diglycidyl ether [1675-54-3] (Vol. 47, Vol. 71; 1999)

Bisulfites (Vol. 54; 1992)

Blue VRS [129-17-9] (Vol. 16, Suppl. 7; 1987)

Brilliant Blue FCF, disodium salt [3844-45-9] (Vol. 16, Suppl. 7; 1987)

Bromochloroacetonitrile [83463-62-1] (Vol. 52, Vol. 71; 1999)

Bromoethane [74-96-4] (Vol. 52, Vol. 71; 1999)

Bromoform [75-25-2] (Vol. 52, Vol. 71; 1999)

n-Butyl acrylate [141-32-2] (Vol. 39, Suppl. 7, Vol. 71; 1999)

Butylated hydroxytoluene (BHT) [128-37-0] (Vol. 40, Suppl. 7; 1987)

Butyl benzyl phthalate [85-68-7] (Vol. 73; 1999)

g-Butyrolactone [96-48-0] (Vol. 11, Suppl. 7, Vol. 71; 1999)

Caffeine [58-08-2] (Vol. 51; 1991)

Cantharidin [56-25-7] (Vol. 10, Suppl. 7; 1987)

Captan [133-06-2] (Vol. 30, Suppl. 7; 1987)

Carbaryl [63-25-2] (Vol. 12, Suppl. 7; 1987)

Carbazole [86-74-8] (Vol. 32, Suppl. 7, Vol. 71; 1999)

3-Carbethoxypsoralen [20073-24-9] (Vol. 40, Suppl. 7; 1987)

Carmoisine [3567-69-9] (Vol. 8, Suppl. 7; 1987)

Carrageenan [9000-07-1], native (Vol. 31, Suppl. 7; 1987)

Chloral [75-87-6] (Vol. 63; 1995)

Chloral hydrate [302-17-0] (Vol. 63; 1995)

Chlordimeform [6164-98-3] (Vol. 30, Suppl. 7; 1987)

Chlorinated drinking-water (Vol. 52; 1991)

Chloroacetonitrile [107-14-2] (Vol. 52, Vol. 71; 1999)

Chlorobenzilate [510-15-6] (Vol. 30, Suppl. 7; 1987)

Chlorodibromomethane [124-48-1] (Vol. 52, Vol. 71; 1999)

Chlorodifluoromethane [75-45-6] (Vol. 41, Suppl. 7, Vol. 71; 1999)

Chloroethane [75-00-3] (Vol. 52, Vol. 71; 1999)

Chlorofluoromethane [593-70-4] (Vol. 41, Suppl. 7, Vol. 71; 1999)

3-Chloro-2-methylpropene [563-47-3] (Vol. 63; 1995)

4-Chloro-meta-phenylenediamine [5131-60-2] (Vol. 27, Suppl. 7; 1987)

Chloronitrobenzenes [88-73-3; 121-73-3; 100-00-5] (Vol. 65; 1996)

Chloropropham [101-21-3] (Vol. 12, Suppl. 7; 1987)

Chloroquine [54-05-7] (Vol. 13, Suppl. 7; 1987)

5-Chloro-ortho-toluidine [95-79-4] (Vol. 77; 2000)

2-Chloro-1,1,1-trifluoroethane [75-88-7] (Vol. 41, Suppl. 7, Vol. 71; 1999)

Cholesterol [57-88-5] (Vol. 31, Suppl. 7; 1987)

Chromium[iII] compounds (Vol. 49; 1990)

Chromium [7440-47-3], metallic (Vol. 49; 1990)

Chrysene [218-01-9] (Vol. 32, Suppl. 7; 1987)

Chrysoidine [532-82-1] (Vol. 8, Suppl. 7; 1987)

CI Acid Orange 3 [6373-74-6] (Vol. 57; 1993)

Cimetidine [51481-61-9] (Vol. 50; 1990)

Cinnamyl anthranilate [87-29-6] (Vol. 31, Suppl. 7, Vol. 77; 2000)

CI Pigment Red 3 [2425-85-6] (Vol. 57; 1993)

Citrinin [518-75-2] (Vol. 40, Suppl. 7; 1987)

Clofibrate [637-07-0] (Vol. 66; 1996)

Clomiphene citrate [50-41-9] (Vol. 21, Suppl. 7; 1987)

Coal dust (Vol. 68; 1997)

Copper 8-hydroxyquinoline [10380-28-6] (Vol. 15, Suppl. 7; 1987)

Coronene [191-07-1] (Vol. 32, Suppl. 7; 1987)

Coumarin [91-64-5] (Vol. 10, Suppl. 7, Vol. 77; 2000)

meta-Cresidine [102-50-1] (Vol. 27, Suppl. 7; 1987)

Crotonaldehyde [4170-30-3] (Vol. 63; 1995)

Cyclamates [sodium cyclamate, 139-05-9] (Vol. 73; 1999)

Cyclochlorotine [12663-46-6] (Vol. 10, Suppl. 7; 1987)

Cyclohexanone [108-94-1] (Vol. 47, Vol. 71; 1999)

Cyclopenta[cd]pyrene [27208-37-3] (Vol. 32, Suppl. 7; 1987)

D & C Red No. 9 [5160-02-1] (Vol. 57; 1993)

Dapsone [80-08-0] (Vol. 24, Suppl. 7; 1987)

Decabromodiphenyl oxide [1163-19-5] (Vol. 48, Vol. 71; 1999)

Deltamethrin [52918-63-5] (Vol. 53; 1991)

Diacetylaminoazotoluene [83-63-6] (Vol. 8, Suppl. 7; 1987)

Diallate [2303-16-4] (Vol. 30, Suppl. 7; 1987)

1,2-Diamino-4-nitrobenzene [99-56-9] (Vol. 16, Suppl. 7; 1987)

1,4-Diamino-2-nitrobenzene [5307-14-2] (Vol. 57; 1993)

2,5-Diaminotoluene [95-70-5] (Vol. 16, Suppl. 7; 1987)

epam [439-14-5] (Vol. 66; 1996)

omethane [334-88-3] (Vol. 7, Suppl. 7; 1987)

Dibenz[a,c]anthracene [215-58-7] (Vol. 32, Suppl. 7; 1987)

Dibenz[a,j]anthracene [224-41-9] (Vol. 32, Suppl. 7; 1987)

Dibenzo-para-dioxin (Vol. 69; 1997)

Dibenzo[a,e]fluoranthene [5385-75-1] (Vol. 32, Suppl. 7; 1987)

Dibenzo[h,rst]pentaphene [192-47-2] (Vol. 3, Suppl. 7; 1987)

Dibromoacetonitrile [3252-43-5] (Vol. 52, Vol. 71; 1999)

Dichloroacetic acid [79-43-6] (Vol. 63; 1995)

Dichloroacetonitrile [3018-12-0] (Vol. 52, Vol. 71; 1999)

Dichloroacetylene [7572-29-4] (Vol. 39, Suppl. 7, Vol. 71; 1999)

meta-Dichlorobenzene [541-73-1] (Vol. 73; 1999)

ortho-Dichlorobenzene [95-50-1] (Vol. 73; 1999)

trans-1,4-Dichlorobutene [110-57-6] (Vol. 15, Suppl. 7, Vol. 71; 1999)

2,6-Dichloro-para-phenylenediamine [609-20-1] (Vol. 39, Suppl. 7; 1987)

1,2-Dichloropropane [78-87-5] (Vol. 41, Suppl. 7, Vol. 71; 1999)

Dicofol [115-32-2] (Vol. 30, Suppl. 7; 1987)

Didanosine [69655-05-6] (Vol. 76; 2000)

Dieldrin [60-57-1] (Vol. 5, Suppl. 7; 1987)

Diethanolamine [111-42-2] (Vol. 77; 2000)

Di(2-ethylhexyl) adipate [103-23-1] (Vol. 29, Suppl. 7, Vol. 77; 2000)

Di(2-ethylhexyl) phthalate [117-81-7] (Vol. 29, Suppl. 7, Vol. 77; 2000)

[N.B.-Other relevant data taken into consideration in making the overall

evaluation]

Dihydroxymethylfuratrizine [794-93-4] (Vol. 24, Suppl. 7; 1987)

Dimethoxane [828-00-2] (Vol. 15, Suppl. 7; 1987)

3,3'-Dimethoxybenzidine-4,4'-diisocyanate [91-93-0] (Vol. 39, Suppl. 7;

1987)

para-Dimethylaminoazobenzenediazo sodium sulfonate [140-56-7] (Vol. 8,

Suppl. 7; 1987)

4,4'-Dimethylangelicin [22975-76-4] plus ultraviolet A radiation (Suppl. 7;

1987)

4,5'-Dimethylangelicin [4063-41-6] plus ultraviolet A radiation (Suppl. 7;

1987)

N,N-Dimethylaniline [121-69-7] (Vol. 57; 1993)

Dimethylformamide [68-12-2] (Vol. 47; Vol. 71; 1999)

Dimethyl hydrogen phosphite [868-85-9] (Vol. 48, Vol. 71; 1999)

1,4-Dimethylphenanthrene [22349-59-3] (Vol. 32, Suppl. 7; 1987)

1,3-Dinitropyrene [75321-20-9] (Vol. 46; 1989)

3,5-Dinitrotoluene [618-85-9] (Vol. 65; 1996)

Dinitrosopentamethylenetetramine [101-25-7] (Vol. 11, Suppl. 7; 1987)

2,4'-Diphenyldiamine [492-17-1] (Vol. 16, Suppl. 7; 1987)

Disperse Yellow 3 [2832-40-8] (Vol. 48; 1990)

Disulfiram [97-77-8] (Vol. 12, Suppl. 7; 1987)

Dithranol [1143-38-0] (Vol. 13; Suppl. 7; 1987)

Doxefazepam [40762-15-0] (Vol. 66; 1996)

Droloxifene [82413-20-5] (Vol. 66; 1996)

Dulcin [150-69-6] (Vol. 12, Suppl. 7; 1987)

Endrin [72-20-8] (Vol. 5, Suppl. 7; 1987)

Eosin [15086-94-9] (Vol. 15, Suppl. 7; 1987)

3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclo-hexane

carboxylate [141-37-7]

(Vol. 11, Suppl. 7, Vol. 71; 1999)

cis-9,10-Epoxystearic acid [2443-39-2] (Vol. 11, Suppl. 7, Vol. 71; 1999)

Estazolam [29975-16-4] (Vol. 66; 1996)

Ethionamide [536-33-4] (Vol. 13, Suppl. 7; 1987)

Ethylene [74-85-1] (Vol. 60; 1994)

Ethylene sulfide [420-12-2] (Vol. 11, Suppl. 7; 1987)

2-Ethylhexyl acrylate [103-11-7] (Vol. 60; 1994)

Ethyl selenac [5456-28-0] (Vol. 12, Suppl. 7; 1987)

Ethyl tellurac [20941-65-5] (Vol. 12, Suppl. 7; 1987)

Eugenol [97-53-0] (Vol. 36, Suppl. 7; 1987)

blue [314-13-6] (Vol. 8, Suppl. 7; 1987)

Fast Green FCF [2353-45-9] (Vol. 16, Suppl. 7; 1987)

Fenvalerate [51630-58-1] (Vol. 53; 1991)

Ferbam [14484-64-1] (Vol. 12, Suppl. 7; 1987)

Ferric oxide [1309-37-1] (Vol. 1, Suppl. 7; 1987)

Fluometuron [2164-17-2] (Vol. 30, Suppl. 7; 1987)

Fluoranthene [206-44-0] (Vol. 32, Suppl. 7; 1987)

Fluorene [86-73-7] (Vol. 32, Suppl. 7; 1987)

Fluorescent lighting (Vol. 55; 1992)

Fluorides (inorganic, used in drinking-water) (Vol. 27, Suppl. 7; 1987)

5-Fluorouracil [51-21-8] (Vol. 26, Suppl. 7; 1987)

Foreign bodies, implanted in tissues (Vol. 74; 1999)

Metallic chromium or titanium, cobalt-based, chromium-based and

titanium-based alloys, stainless steel and depleted uranium

Furazolidone [67-45-8] (Vol. 31, Suppl. 7; 1987)

Furfural [98-01-1] (Vol. 63; 1995)

Furosemide (Frusemide) [54-31-9] (Vol. 50; 1990)

Gemfibrozil [25812-30-0] (Vol. 66; 1996)

Glass filaments (Vol. 43; 1988)

Glycidyl oleate [5431-33-4] (Vol. 11, Suppl. 7; 1987)

Glycidyl stearate [7460-84-6] (Vol. 11, Suppl. 7; 1987)

Guinea Green B [4680-78-8] (Vol. 16, Suppl. 7; 1987)

Gyromitrin [16568-02-8] (Vol. 31, Suppl. 7; 1987)

Haematite [1317-60-8] (Vol. 1, Suppl. 7; 1987)

HC Blue No. 2 [33229-34-4] (Vol. 57; 1993)

HC Red No. 3 [2871-01-4] (Vol. 57; 1993)

HC Yellow No. 4 [59820-43-8] (Vol. 57; 1993)

Hepatitis D virus (Vol. 59; 1994)

Hexachlorobutadiene [87-68-3] (Vol. 73; 1999)

Hexachlorophene [70-30-4] (Vol. 20, Suppl. 7; 1987)

Human T-cell lymphotropic virus type II (Vol. 67; 1996)

Hycanthone mesylate [23255-93-8] (Vol. 13, Suppl. 7; 1987)

Hydralazine [86-54-4] (Vol. 24, Suppl. 7; 1987)

Hydrochloric acid [7647-01-0] (Vol. 54; 1992)

Hydrochlorothiazide [58-93-5] (Vol. 50; 1990)

Hydrogen peroxide [7722-84-1] (Vol. 36, Suppl. 7, Vol. 71; 1999)

Hydroquinone [123-31-9] (Vol. 15, Suppl. 7, Vol. 71; 1999)

4-Hydroxyazobenzene [1689-82-3] (Vol. 8, Suppl. 7; 1987)

8-Hydroxyquinoline [148-24-3] (Vol. 13, Suppl. 7; 1987)

Hydroxysenkirkine [26782-43-4] (Vol. 10, Suppl. 7; 1987)

Hydroxyurea [127-07-1] (Vol. 76; 2000)

Hypochlorite salts (Vol. 52; 1991)

Iron-dextrin complex [9004-51-7] (Vol. 2, Suppl. 7; 1987)

Iron sorbitol-citric acid complex [1338-16-5] (Vol. 2, Suppl. 7; 1987)

Isatidine [15503-86-3] (Vol. 10, Suppl. 7; 1987)

Isonicotinic acid hydrazide (Isoniazid) [54-85-3] (Vol. 4, Suppl. 7; 1987)

Isophosphamide [3778-73-2] (Vol. 26, Suppl. 7; 1987)

Isopropanol [67-63-0] (Vol. 15, Suppl. 7, Vol. 71; 1999)

Isopropyl oils (Vol. 15, Suppl. 7, Vol. 71; 1999)

Isosafrole [120-58-1] (Vol. 10, Suppl. 7; 1987)

ine [6870-67-3] (Vol. 10, Suppl. 7; 1987)

Kaempferol [520-18-3] (Vol. 31, Suppl. 7; 1987)

Lauroyl peroxide [105-74-8] (Vol. 36, Suppl. 7, Vol. 71; 1999)

Lead, organo [75-74-1], [78-00-2] (Vol. 23, Suppl. 7; 1987)

Light Green SF [5141-20-8] (Vol. 16, Suppl. 7; 1987)

d-Limonene [5989-27-5] (Vol. 73; 1999)

Luteoskyrin [21884-44-6] (Vol. 10, Suppl. 7; 1987)

Malathion [121-75-5] (Vol. 30, Suppl. 7; 1987)

Maleic hydrazide [123-33-1] (Vol. 4, Suppl. 7; 1987)

Malonaldehyde [542-78-9] (Vol. 36, Suppl. 7, Vol. 71; 1999)

Maneb [12427-38-2] (Vol. 12, Suppl. 7; 1987)

Mannomustine dihydrochloride [551-74-6] (Vol. 9, Suppl. 7; 1987)

Medphalan [13045-94-8] (Vol. 9, Suppl. 7; 1987)

Melamine [108-78-1] (Vol. 73; 1999)

6-Mercaptopurine [50-44-2] (Vol. 26, Suppl. 7; 1987)

Mercury [7439-97-6] and inorganic mercury compounds (Vol. 58; 1993)

Metabisulfites (Vol. 54; 1992)

Methotrexate [59-05-2] (Vol. 26, Suppl. 7; 1987)

Methoxychlor [72-43-5] (Vol. 20, Suppl. 7; 1987)

Methyl acrylate [96-33-3] (Vol. 39, Suppl. 7, Vol. 71; 1999)

5-Methylangelicin [73459-03-7] plus ultraviolet A radiation (Suppl. 7; 1987)

Methyl bromide [74-83-9] (Vol. 41, Suppl. 7, Vol. 71; 1999)

Methyl tert-butyl ether [1634-04-4] (Vol. 73; 1999)

Methyl carbamate [598-55-0] (Vol. 12, Suppl. 7; 1987)

Methyl chloride [74-87-3] (Vol. 41, Suppl. 7, Vol. 71; 1999)

1-Methylchrysene [3351-28-8] (Vol. 32, Suppl. 7; 1987)

2-Methylchrysene [3351-32-4] (Vol. 32, Suppl. 7; 1987)

3-Methylchrysene [3351-31-3] (Vol. 32, Suppl. 7; 1987)

4-Methylchrysene [3351-30-2] (Vol. 32, Suppl. 7; 1987)

6-Methylchrysene [1705-85-7] (Vol. 32, Suppl. 7; 1987)

N-Methyl-N,4-dinitrosoaniline [99-80-9] (Vol. 1, Suppl. 7; 1987)

4,4'-Methylene bis(N,N-dimethyl)benzenamine [101-61-1] (Vol. 27, Suppl. 7;

1987)

4,4'-Methylenediphenyl diisocyanate [101-68-8] (Vol. 19, Suppl. 7, Vol. 71;

1999)

2-Methylfluoranthene [33543-31-6] (Vol. 32, Suppl. 7; 1987)

3-Methylfluoranthene [1706-01-0] (Vol. 32, Suppl. 7; 1987)

Methylglyoxal [78-98-8] (Vol. 51; 1991)

Methyl iodide [74-88-4] (Vol. 41, Suppl. 7, Vol. 71; 1999)

Methyl methacrylate [80-62-6] (Vol. 60; 1994)

N-Methylolacrylamide [90456-67-0] (Vol. 60; 1994)

Methyl parathion [298-00-0] (Vol. 30, Suppl. 7; 1987)

1-Methylphenanthrene [832-69-9] (Vol. 32, Suppl. 7; 1987)

7-Methylpyrido[3,4-c]psoralen [85878-63-3] (Vol. 40, Suppl. 7; 1987)

Methyl red [493-52-7] (Vol. 8, Suppl. 7; 1987)

Methyl selenac [144-34-3] (Vol. 12, Suppl. 7; 1987)

Modacrylic fibres (Vol. 19, Suppl. 7; 1987)

Monuron [150-68-5] (Vol. 53; 1991)

Morpholine [110-91-8] (Vol. 47, Vol. 71; 1999)

Musk ambrette [83-66-9] (Vol. 65; 1996)

Musk xylene [81-15-2] (Vol. 65; 1996)

1,5-Naphthalenediamine [2243-62-1] (Vol. 27, Suppl. 7; 1987)

1,5-Naphthalene diisocyanate [3173-72-6] (Vol. 19, Suppl. 7, Vol. 71; 1999)

1-Naphthylamine [134-32-7] (Vol. 4, Suppl. 7; 1987)

1-Naphthylthiourea (ANTU) [86-88-4] (Vol. 30, Suppl. 7; 1987)

Nithiazide [139-94-6] (Vol. 31, Suppl. 7; 1987)

5-Nitro-ortho-anisidine [99-59-2] (Vol. 27, Suppl. 7; 1987)

9-Nitroanthracene [602-60-8] (Vol. 33, Suppl. 7; 1987)

7-Nitrobenz[a]anthracene [20268-51-3] (Vol. 46; 1989)

6-Nitrobenzo[a]pyrene [63041-90-7] (Vol. 46; 1989)

4-Nitrobiphenyl [92-93-3] (Vol. 4, Suppl. 7; 1987)

3-Nitrofluoranthene [892-21-7] (Vol. 33, Suppl. 7; 1987)

Nitrofural (Nitrofurazone) [59-87-0] (Vol. 50; 1990)

Nitrofurantoin [67-20-9] (Vol. 50; 1990)

1-Nitronaphthalene [86-57-7] (Vol. 46; 1989)

2-Nitronaphthalene [581-89-5] (Vol. 46; 1989)

3-Nitroperylene [20589-63-3] (Vol. 46; 1989)

2-Nitropyrene [789-07-1] (Vol. 46; 1989)

N'-Nitrosoanabasine [37620-20-5] (Vol. 37, Suppl. 7; 1987)

N'-Nitrosoanatabine [71267-22-6] (Vol. 37, Suppl. 7; 1987)

N-Nitrosodiphenylamine [86-30-6] (Vol. 27, Suppl. 7; 1987)

para-Nitrosodiphenylamine [156-10-5] (Vol. 27, Suppl. 7; 1987)

N-Nitrosofolic acid [29291-35-8] (Vol. 17, Suppl. 7; 1987)

N-Nitrosoguvacine [55557-01-2] (Vol. 37, Suppl. 7; 1987)

N-Nitrosoguvacoline [55557-02-3] (Vol. 37, Suppl. 7; 1987)

N-Nitrosohydroxyproline [30310-80-6] (Vol. 17, Suppl. 7; 1987)

3-(N-Nitrosomethylamino)propionaldehyde [85502-23-4] (Vol. 37, Suppl. 7;

1987)

4-(N-Nitrosomethylamino)-4-(3-pyridyl)-1-butanal (NNA) [64091-90-3] (Vol.

37, Suppl. 7; 1987)

N-Nitrosoproline [7519-36-0] (Vol. 17, Suppl. 7; 1987)

Nitrotoluenes [88-72-2; 99-08-1; 99-99-0] (Vol. 65; 1996)

5-Nitro-ortho-toluidine [99-55-8] (Vol. 48; 1990)

Nitrovin [804-36-4] (Vol. 31, Suppl. 7; 1987)

Nylon 6 [25038-54-4] (Vol. 19, Suppl. 7; 1987)

Oestradiol mustard [22966-79-6] (Vol. 9, Suppl. 7; 1987)

Opisthorchis felineus (infection with) (Vol. 61; 1994)

Orange I [523-44-4] (Vol. 8, Suppl. 7; 1987)

Orange G [1936-15-8] (Vol. 8, Suppl. 7; 1987)

Oxyphenbutazone [129-20-4] (Vol. 13, Suppl. 7; 1987)

Palygorskite (attapulgite) [12174-11-7] (short fibres, < 5 micrometers)

(Vol. 68; 1997)

Paracetamol (Acetaminophen) [103-90-2] (Vol. 73; 1999)

Parasorbic acid [10048-32-5] (Vol. 10, Suppl. 7; 1987)

Parathion [56-38-2] (Vol. 30, Suppl. 7; 1987)

Patulin [149-29-1] (Vol. 40, Suppl. 7; 1987)

Penicillic acid [90-65-3] (Vol. 10, Suppl. 7; 1987)

Pentachloroethane [76-01-7] (Vol. 41, Suppl. 7, Vol. 71; 1999)

Permethrin [52645-53-1] (Vol. 53; 1991)

Perylene [198-55-0] (Vol. 32, Suppl. 7; 1987)

Petasitenine [60102-37-6] (Vol. 31, Suppl. 7; 1987)

Phenanthrene [85-01-8] (Vol. 32, Suppl. 7; 1987)

Phenelzine sulfate [156-51-4] (Vol. 24, Suppl. 7; 1987)

Phenicarbazide [103-03-7] (Vol. 12, Suppl. 7; 1987)

Phenol [108-95-2] (Vol. 47, Vol. 71; 1999)

Phenylbutazone [50-33-9] (Vol. 13, Suppl. 7; 1987)

meta-Phenylenediamine [108-45-2] (Vol. 16, Suppl. 7; 1987)

para-Phenylenediamine [106-50-3] (Vol. 16, Suppl. 7; 1987)

N-Phenyl-2-naphthylamine [135-88-6] (Vol. 16, Suppl. 7; 1987)

ortho-Phenylphenol [90-43-7] (Vol. 73; 1999)

Picloram [1918-02-1] (Vol. 53; 1991)

Piperonyl butoxide [51-03-6] (Vol. 30, Suppl. 7; 1987)

Polyacrylic acid [9003-01-4] (Vol. 19, Suppl. 7; 1987)

Polychlorinated dibenzo-para-dioxins (other than

2,3,7,8-tetrachlorodibenzo-para-dioxin) (Vol. 69; 1997)

Polychlorinated dibenzofurans (Vol. 69; 1997)

Polychloroprene [9010-98-4] (Vol. 19, Suppl. 7; 1987)

Polyethylene [9002-88-4] (Vol. 19, Suppl. 7; 1987)

Polymethylene polyphenyl isocyanate [9016-87-9] (Vol. 19, Suppl. 7; 1987)

Polymethyl methacrylate [9011-14-7] (Vol. 19, Suppl. 7; 1987)

Polypropylene [9003-07-0] (Vol. 19, Suppl. 7; 1987)

Polystyrene [9003-53-6] (Vol. 19, Suppl. 7; 1987)

Polytetrafluoroethylene [9002-84-0] (Vol. 19, Suppl. 7; 1987)

Polyurethane foams [9009-54-5] (Vol. 19, Suppl. 7; 1987)

Polyvinyl acetate [9003-20-7] (Vol. 19, Suppl. 7; 1987)

Polyvinyl alcohol [9002-89-5] (Vol. 19, Suppl. 7; 1987)

Polyvinyl chloride [9002-86-2] (Vol. 19, Suppl. 7; 1987)

Polyvinyl pyrrolidone [9003-39-8] (Vol. 19, Suppl. 7, Vol. 71; 1999)

Ponceau SX [4548-53-2] (Vol. 8, Suppl. 7; 1987)

Potassium bis(2-hydroxyethyl)dithiocarbamate [23746-34-1] (Vol. 12, Suppl.

7; 1987)

Prazepam [2955-38-6] (Vol. 66; 1996)

Prednimustine [29069-24-7] (Vol. 50; 1990)

Prednisone [53-03-2] (Vol. 26, Suppl. 7; 1987)

Proflavine salts (Vol. 24, Suppl. 7; 1987)

Pronetalol hydrochloride [51-02-5] (Vol. 13, Suppl. 7; 1987)

Propham [122-42-9] (Vol. 12, Suppl. 7; 1987)

n-Propyl carbamate [627-12-3] (Vol. 12, Suppl. 7; 1987)

Propylene [115-07-1] (Vol. 60; 1994)

Ptaquiloside [87625-62-5] (Vol. 40, Suppl. 7; 1987)

Pyrene [129-00-0] (Vol. 32, Suppl. 7; 1987)

Pyridine [110-86-1] (Vol. 77; 2000)

Pyrido[3,4-c]psoralen [85878-62-2] (Vol. 40, Suppl. 7; 1987)

Pyrimethamine [58-14-0] (Vol. 13, Suppl. 7; 1987)

Quercetin [117-39-5] (Vol. 73; 1999)

para-Quinone [106-51-4] (Vol. 15, Suppl. 7, Vol. 71; 1999)

Quintozene (Pentachloronitrobenzene) [82-68-8] (Vol. 5, Suppl. 7; 1987)

Reserpine [50-55-5] (Vol. 24, Suppl. 7; 1987)

Resorcinol [108-46-3] (Vol. 15, Suppl. 7, Vol. 71, 1999)

Retrorsine [480-54-6] (Vol. 10, Suppl. 7; 1987)

Rhodamine B [81-88-9] (Vol. 16, Suppl. 7; 1987)

Rhodamine 6G [989-38-8] (Vol. 16, Suppl. 7; 1987)

Riddelliine [23246-96-0] (Vol. 10, Suppl. 7; 1987)

Rifampicin [13292-46-1] (Vol. 24, Suppl. 7; 1987)

Ripazepam [26308-28-1] (Vol. 66; 1996)

Rugulosin [23537-16-8] (Vol. 40, Suppl. 7; 1987)

Saccharated iron oxide [8047-67-4] (Vol. 2, Suppl. 7; 1987)

Saccharin [81-07-2] and its salts (Vol. 73; 1999)

(NB: Overall evaluation downgraded from 2B to 3 with supporting evidence

from other data relevant to carcinogenicity and its mechanisms)

Scarlet Red [85-83-6] (Vol. 8, Suppl. 7; 1987)

Schistosoma mansoni (infection with) (Vol. 61; 1994)

Selenium [7782-49-2] and selenium compounds (Vol. 9, Suppl. 7; 1987)

Semicarbazide hydrochloride [563-41-7] (Vol. 12, Suppl. 7; 1987)

Seneciphylline [480-81-9] (Vol. 10, Suppl. 7; 1987)

Senkirkine [2318-18-5] (Vol. 31, Suppl. 7; 1987)

Sepiolite [15501-74-3] (Vol. 68; 1997)

Shikimic acid [138-59-0] (Vol. 40, Suppl. 7; 1987)

Silica [7631-86-9], amorphous (Vol. 68; 1997)

Simazine [122-34-9] (Vol. 73; 1999)

Sodium chlorite [7758-19-2] (Vol. 52; 1991)

Sodium diethyldithiocarbamate [148-18-5] (Vol. 12, Suppl. 7; 1987)

Spironolactone [52-01-7] (Vol. 24, Suppl. 7; 1987)

Styrene-acrylonitrile copolymers [9003-54-7] (Vol. 19, Suppl. 7; 1987)

Styrene-butadiene copolymers [9003-55-8] (Vol. 19, Suppl. 7; 1987)

Succinic anhydride [108-30-5] (Vol. 15, Suppl. 7; 1987)

Sudan I [842-07-9] (Vol. 8, Suppl. 7; 1987)

Sudan II [3118-97-6] (Vol. 8, Suppl. 7; 1987)

Sudan III [85-86-9] (Vol. 8, Suppl. 7; 1987)

Sudan Brown RR [6416-57-5] (Vol. 8, Suppl. 7; 1987)

Sudan Red 7B [6368-72-5] (Vol. 8, Suppl. 7; 1987)

Sulfafurazole (Sulfisoxazole) [127-69-5] (Vol. 24, Suppl. 7; 1987)

Sulfamethoxazole [723-46-6] (Vol. 24, Suppl. 7; 1987)

Sulfites (Vol. 54; 1992)

Sulfur dioxide [7446-09-5] (Vol. 54; 1992)

Sunset Yellow FCF [2783-94-0] (Vol. 8, Suppl. 7; 1987)

Surgical implants (Vol. 74; 1999)

Orthopaedic implants and devices, of complex composition

Cardiac pacemakers

Dental materials

Ceramic materials

Surgical implants, female breast reconstruction, silicone (Vol. 74; 1999)

Symphytine [22571-95-5] (Vol. 31, Suppl. 7; 1987)

Talc [14807-96-6], not containing asbestiform fibres (Vol. 42, Suppl. 7;

1987)

Tannic acid [1401-55-4] and tannins (Vol. 10, Suppl. 7; 1987)

Temazepam [846-50-4] (Vol. 66; 1996)

2,2',5,5'-Tetrachlorobenzidine [15721-02-5] (Vol. 27, Suppl. 7; 1987)

1,1,1,2-Tetrachloroethane [630-20-6] (Vol. 41, Suppl. 7, Vol. 71; 1999)

1,1,2,2-Tetrachloroethane [79-34-5] (Vol. 20, Suppl. 7, Vol. 71; 1999)

Tetrachlorvinphos [22248-79-9] (Vol. 30, Suppl. 7; 1987)

Tetrakis(hydroxymethyl)phosphonium salts (Vol. 48, Vol. 71; 1999)

Theobromine [83-67-0] (Vol. 51; 1991)

Theophylline [58-55-9] (Vol. 51; 1991)

Thiouracil [141-90-2] (Vol. 7, Suppl. 7; 1987)

Thiram [137-26-8] (Vol. 53; 1991)

Titanium dioxide [13463-67-7] (Vol. 47; 1989)

Toluene [108-88-3] (Vol. 47, Vol. 71; 1999)

Toremifene [89778-26-7] (Vol. 66; 1996)

Toxins derived from Fusarium graminearum, F. culmorum and F. crookwellense

(Vol. 56; 1993)

Toxins derived from Fusarium sporotrichioides (Vol. 56; 1993)

Trichlorfon [52-68-6] (Vol. 30, Suppl. 7; 1987)

Trichloroacetic acid [76-03-9] (Vol. 63; 1995)

Trichloroacetonitrile [545-06-2] (Vol. 52, Vol. 71; 1999)

1,1,1-Trichloroethane [71-55-6] (Vol. 20, Suppl. 7, Vol. 71; 1999)

1,1,2-Trichloroethane [79-00-5] (Vol. 52, Vol. 71; 1999)

Triethanolamine [102-71-6] (Vol. 77; 2000)

Triethylene glycol diglycidyl ether [1954-28-5] (Vol. 11, Suppl. 7, Vol. 71;

1999)

Trifluralin [1582-09-8] (Vol. 53; 1991)

4,4',6-Trimethylangelicin [90370-29-9] plus ultraviolet A radiation (Suppl.

7; 1987)

2,4,5-Trimethylaniline [137-17-7] (Vol. 27, Suppl. 7; 1987)

2,4,6-Trimethylaniline [88-05-1] (Vol. 27, Suppl. 7; 1987)

4,5',8-Trimethylpsoralen [3902-71-4] (Vol. 40, Suppl. 7; 1987)

2,4,6-Trinitrotoluene [118-96-7] (Vol. 65; 1996)

Triphenylene [217-59-4] (Vol. 32, Suppl. 7; 1987)

Tris(aziridinyl)-para-benzoquinone (Triaziquone) [68-76-8] (Vol. 9, Suppl.

7; 1987)

Tris(1-aziridinyl)phosphine oxide [545-55-1] (Vol. 9, Suppl. 7; 1987)

2,4,6-Tris(1-aziridinyl)-s-triazine [51-18-3] (Vol. 9, Suppl. 7; 1987)

Tris(2-chloroethyl) phosphate [115-96-8] (Vol. 48, Vol. 71; 1999)

1,2,3-Tris(chloromethoxy)propane [38571-73-2] (Vol. 15, Suppl. 7, Vol. 71;

1999)

Tris(2-methyl-1-aziridinyl)phosphine oxide [57-39-6] (Vol. 9, Suppl. 7;

1987)

Vat Yellow 4 [128-66-5] (Vol. 48; 1990)

Vinblastine sulfate [143-67-9] (Vol. 26, Suppl. 7; 1987)

Vincristine sulfate [2068-78-2] (Vol. 26, Suppl. 7; 1987)

Vinyl chloride-vinyl acetate copolymers [9003-22-9] (Vol. 19, Suppl. 7;

1987)

Vinylidene chloride [75-35-4] (Vol. 39, Suppl. 7, Vol. 71; 1999)

Vinylidene chloride-vinyl chloride copolymers [9011-06-7] (Vol. 19, Suppl.

7; 1987)

Vinylidene fluoride [75-38-7] (Vol. 39, Suppl. 7, Vol. 71; 1999)

N-Vinyl-2-pyrrolidone [88-12-0] (Vol. 19, Suppl. 7, Vol. 71; 1999)

Vinyl toluene [25013-15-4] (Vol. 60; 1994)

Vitamin K [12001-79-5] substances (Vol. 76; 2000)

Wollastonite [13983-17-0] (Vol. 68; 1997)

Xylenes [1330-20-7] (Vol. 47, Vol. 71; 1999)

2,4-Xylidine [95-68-1] (Vol. 16, Suppl. 7; 1987)

2,5-Xylidine [95-78-3] (Vol. 16, Suppl. 7; 1987)

Yellow AB [85-84-7] (Vol. 8, Suppl. 7; 1987)

Yellow OB [131-79-3] (Vol. 8, Suppl. 7; 1987)

Zectran [315-18-4] (Vol. 12, Suppl. 7; 1987)

Zeolites [1318-02-1] other than erionite (clinoptilolite, phillipsite,

mordenite, non-fibrous Japanese zeolite, synthetic zeolites) (Vol. 68; 1997)

Zineb [12122-67-7] (Vol. 12, Suppl. 7; 1987)

Ziram [137-30-4] (Vol. 53; 1991)

Mixtures

Betel quid, without tobacco (Vol. 37, Suppl. 7; 1987)

Bitumens [8052-42-4], steam-refined, cracking-residue and air-refined (Vol.

35, Suppl. 7; 1987)

Crude oil [8002-05-9] (Vol. 45; 1989)

Diesel fuels, distillate (light) (Vol. 45; 1989)

Fuel oils, distillate (light) (Vol. 45; 1989)

Jet fuel (Vol. 45; 1989)

Mate (Vol. 51; 1991)

Mineral oils, highly-refined (Vol. 33, Suppl. 7; 1987)

Petroleum solvents (Vol. 47; 1989)

Printing inks (Vol. 65; 1996)

Tea (Vol. 51; 1991)

Terpene polychlorinates (StrobaneR) [8001-50-1] (Vol. 5, Suppl. 7; 1987)

Exposure circumstances

Flat-glass and specialty glass (manufacture of) (Vol. 58; 1993)

Hair colouring products (personal use of) (Vol. 57; 1993)

Leather goods manufacture (Vol. 25, Suppl. 7; 1987)

Leather tanning and processing (Vol. 25, Suppl. 7; 1987)

Lumber and sawmill industries (including logging) (Vol. 25, Sup

Has the ultimate cancer cure arrived?

Hello Folks,

Listmember

pkelly@...

just posted this forward on the medical qi gong list.

It looks like a big breakthrough in cancer therapy.

Green

This is an interesting post from the Cancercure support group.

Have a great weekend.

For those who missed it, here is the news taken from

yesterday's Hindustan Times. My Indian friends tell me that

this is practically the New York Times of India.

====================================================

Has the ultimate cancer cure arrived?

PTI

(Hyderabaad, May 28)

INDIAN CANCER researchers have taken a giant step on the road to

discovering the ultimate cancer cure by developing a drug that

selectively targets the cancer cells without harming the healthy

ones.

Researchers in Kolkata claim that patients in " very advanced stages "

of cancer for whom all other treatments had failed have been brought

back to " excellent " health with the help of a drug formulation they

have developed after research spanning more than a decade.

" We have what we think magic bullet against cancer, " says Manju Ray,

a biochemist at the Indian Association of the Cultivation of Science

(IACS) where the drug was developed under a project funded by the

Department of Science and Technology and the Council of Scientific

and Industrial Research.

Most currently available anti-cancer drugs are toxic because they

also damage the normal cells. Ray says the IACS formulation,

containing " Methylglyoxal " as the lead ingredient, combats only the

diseased cells, the cherished goal of cancer researchers worldwide.

Methylglyoxal is a metabolite in the human body produced during

glucose breakdown.

Others involved in the project are Swapna Ghosh of IACS, Manoj Kar

and Subhankar Ray of the University College of Science, and Santajit

Datta, a medical practitioner. Results of human trial conducted by

them with the new drug have recently appeared in the Indian Journal

of Physics.

While Americans are going ga-ga with their new anti-cancer

drug " Glivec " - that was featured on the cover of May 28 issue of

Time magazine - the low-profile, cash-strapped Kolkata researchers

have been working quietly for over a decade shunning publicity until

they obtained proof from human trials nine weeks ago.

According to their published paper, the Methylglyoxal-based

forumulation had " a dramatic positive effect on the patients " .

For instance, the condition of 11 out of the 19 patients treated -

most of them in a very advanced stage when the treatment began -- are

now stated to be in " excellent physical condition " . Five are in

stable condition and only three died during the course of the study.

Since the submission of the paper, the number of patients treated has

crossed 40 mark with more than 70 per cent success, according to

Manju Ray.

Most remarkable fact, according to the scientists was that

Methylglyoxal was successful against different types of cancer

unlike " Glivec " which targets only the chronic myeloid leukemia.

Those whose health returned to " excellent " condition after treatment

with Methylglyoxal included patients in " a very advanced stages " of

colon cancer, acute myeloid leukemia, non-Hodgkin's lymphoma, and

cancers of ovary, breast, liver, lung, bone, gall bladder, pancreas

and oral cavity.

The patients were inducted for the trial, from January to June 2000,

after obtaining permission from the Drug Controller General of India,

the scientists said. The drug was administered orally for about six

months with gradual reduction of daily dosage from the initial 25

milligrams per kilogram of body weight.

Researchers said development of the drug was preceded by years of

basic research involving human cancer cells in culture and animal

experiments that showed that Methylglyoxal selectively killed the

cancer cells without affecting normal cells by exploiting " a very

significant " biochemical difference between the two.

Explaining the mechanism of action, the scientists said cancer cells

required a large amount of energy providing substance called ATP

(Adenosine-5-Triphosphate) for survival.

" Methylglyoxal inactivates the enzyme (Glyceraldehyde-3- Phosphate

Dehydrogenase) needed for ATP production in cancer cells and thereby

starves them to death. Normal cells remain unaffected. "

Manju ray said that chemists knew Methylglyoxal molecule for about

four decades and its anti-cancer effects in animals had also been

studied. " But surprisingly, no one bothered to initiate further

research leading to human trials, " she said.

The researchers said concern in some quarters about safety of

Methylglyoxal were not borne out from the clinical trials, which

showed that in combination with protective agent like Ascorbic Acid

and vitamins, the drug Methylglyoxal had no major toxic effect. They

said there was scope for further enhancing the drug's efficacy.

Link to comment
Share on other sites
Guest guest

Guest guest

Posted
Posted

You posted 72 kilobytes of mostly irrelevant data to supply

the following reference:

" Methylglyoxal [78-98-8] (Vol. 51; 1991) "

Until we see this specified article we know nothing of it's

relevance. And you didn't supply any URL to the website.

Bill

posted:

And this list classifies Methylglyoxal as a carcinogenic agent (?)

Overall Evaluations of Carcinogenicity to Humans

As evaluated in IARC Monographs Volumes 1-78 (a total of 869 agents,

mixtures and exposures)

This list contains all hazards evaluated to date, according to the type

of hazard posed and to the type of exposure. Where appropriate, chemical

abstract numbers are given [in square brackets]. For details of the

evaluation, the relevant Monograph should be consulted (volume number

given in round brackets, followed by year of publication of latest

evaluation). Use a free-text search to find a particular compound.

- snip -

..

Link to comment
Share on other sites
Guest guest

Guest guest

Posted
Posted

wrote:

>

>Curiously, the source for this chemical (Methylglyoxal synthase)

>is E. Coli... named by Rife as a pleomorphic from the Bx cancer

>virus... [continued below]

Does all E. coli produce " methylglyoxal synthase, " or only the

engineered variety that is listed in your posted data ?

And what is the website URL ?

I thought E. coli is a naturally occurring bacteria in the human

intestines, and (certain E. coli variety/ies are) supplied in

some probiotic ( " acidophilus " ) formulas, as listed on the label.

The long technical specification which you have supplied does

not describe " THE " source for all " methylglyoxal " -- rather it

is one, synthetic (engineered) source of a related enzyme...

Even if you have somehow uncovered the exact source for the

methylglyoxal in question, that doesn't begin to prove Rife's

opinion is relevant in this case...

Bill

- snip -

TITLE METHYLGLYOXAL SYNTHASE FROM ESCHERICHIA COLI

COMPND MOL_ID: 1;

COMPND 2 MOLECULE: METHYLGLYOXAL SYNTHASE;

COMPND 3 CHAIN: A, B, C;

COMPND 4 EC: 4.2.99.11;

COMPND 5 ENGINEERED: YES

SOURCE MOL_ID: 1;

SOURCE 2 ORGANISM_SCIENTIFIC: ESCHERICHIA COLI;

SOURCE 3 STRAIN: LE392;

- snip -

..

Link to comment
Share on other sites
Guest guest

Guest guest

Posted
Posted

I may be sharing completely irrelevant info here. But it is my understanding

that e coli is the bacteria that they use to make human growth hormone also.

Eli Lily, that is. Apparently since it is a great reproducer and somehow they

use that quality to turn out large amounts of man made growth hormone. Perhaps

they are doing the same thing with this product.

Done

-----Original Message-----

wrote:

>

>Curiously, the source for this chemical (Methylglyoxal synthase)

>is E. Coli... named by Rife as a pleomorphic from the Bx cancer

>virus... [continued below]

Does all E. coli produce " methylglyoxal synthase, " or only the

engineered variety that is listed in your posted data ?

And what is the website URL ?

I thought E. coli is a naturally occurring bacteria in the human

intestines, and (certain E. coli variety/ies are) supplied in

some probiotic ( " acidophilus " ) formulas, as listed on the label.

The long technical specification which you have supplied does

not describe " THE " source for all " methylglyoxal " -- rather it

is one, synthetic (engineered) source of a related enzyme...

Even if you have somehow uncovered the exact source for the

methylglyoxal in question, that doesn't begin to prove Rife's

opinion is relevant in this case...

Bill

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
 Share
Go to topic listing
×
×
  • Create New...